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ABSTRACT 
  
 HIV infection contributes substantially to global morbidity and mortality, 
with no immediate promise of an effective vaccine or cure. One major obstacle to 
vaccine development and therapy is to understand why HIV replication persists in 
a person despite the presence of viral specific immune responses. The emerging 
consensus has been that these immune cells are functionally ‘exhausted’ or 
anergic, and thus, although they can recognize HIV infected cells, they are 
unable to effectively keep up with rapid and dynamic viral replication in an 
individual. Negative checkpoint receptors (NCRs) are associated with immune 
dysfunction during chronic HIV infection. The goal of this study is to characterize 
an emerging NCR, TIGIT, in the context of HIV infection. The overall hypothesis 
is that TIGIT will be increased during HIV infection and limit anti-HIV responses, 
targeting the TIGIT pathway will reinvigorate existing anti-HIV T cell effector 
functions. Thus, these studies were conducted to elucidate the role of TIGIT in 
progressive HIV infection. 
 We have identified a combination of NCR pathways that can be targeted, 
TIGIT and PD-1 that may be responsible, at least in part, for making these 
immune cells dysfunctional and exhausted and thus unable to control the virus. 
We show that by blocking the TIGIT and PD-1 pathway, we can reverse the 
defects of these viral-specific CD8 T cells. Furthermore, we extend our findings 
to the clinically relevant nonhnuman primate model of HIV/AIDS. In addition, we 
identify potential predictors of immune reinvigoration from clinically obtainable 
samples. Our findings will give new directions to vaccines and therapies that will 
potentially reverse these dysfunctional cells and allow them to control HIV 
replication, but also serve in enhanced “shock and kill” HIV curative strategies. 
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DISSERTATION HIGHLIGHTS 
 
• HIV infection leads to an expansion of TIGIT+ CD8 and CD4 T cells in the 
blood and gut 
• TIGIT+ CD4 T cells are associated with HIV persistence 
• TIGIT+ CD8 T cells correlate with disease progression and are regulated 
by common gamma chain cytokines 
• TIGIT selectively dampens HIV-specific CD8 T cell responses 
• Blockade of TIGIT reinvigorates pre-existing anti-HIV CD8 T cell 
responses 
• Co-blockade of TIGIT and PD-L1 synergize to reinvigorate anti-HIV CD8 T 
cell responses than a single blockade alone 
• As a preclinical model we identified similarities and differences between 
huTIGIT and rhTIGIT in a nonhuman primate SIV model of HIV/AIDS 
• cART suppressed HIV infection results in an increase of Fusobacteria 
abundance in the gut  
• Increased abundance of Fusobacteria in the gut is associated with a 
decreased magnitude of anti-HIV CD8 T cell reinvigoration by TIGIT 
blockade 
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CHAPTER 1 
 
INTRODUCTION 
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Epidemiology 
 
 Human immunodeficiency virus (HIV) was introduced to the human 
population between 1915-1941 through multiple zoonotic infections from simian 
immunodeficiency virus (SIV) infected nonhuman primates [3, 4]. A recent study 
suggests that HIV subtype B has been circulating throughout the United States of 
America as a widespread epidemic since 1970 [5]. However, it wasn't until 1981 
when the Centers for Disease Control (CDC) first reported several cases of 
young, homosexual men presenting with Pneumocystis carinii pneumonia and 
Kaposi’s Sarcoma, which is not normally seen in young immunocompetent adults 
[6]. A few weeks later, the CDC reported 26 homosexual men from New York 
and San Francisco with similar symptoms [7]. All individuals showed signs of a 
compromised immune system with a hallmark depletion of cluster of 
differentiation (CD) 4 T cells. Several years later, two independent groups 
identified a blood-borne T cell lymphotropic retrovirus, that was later named HIV, 
as the etiological agent that causes the destruction of the immune system 
leading to acquired immunodeficiency syndrome (AIDS) and the onset of 
opportunistic infections resulting in death [8-10]. 35 years later, HIV has become 
a worldwide pandemic and currently remains a global health concern. In 2015, 
the CDC estimates there were 2.1 million new cases, 36.7 million individuals 
currently living with HIV and 39 million AIDS-related deaths. A majority of the 
infection is focused in Sub-Saharan Africa, which accounts for about 65% of all 
new HIV infections. Cutting edge research along with better treatment 
implementation approaches, increased awareness, and improved prevention has 
slowed worldwide HIV infection rates by 6% since 2010 and AIDS-related deaths 
by 45% since the peak in 2005 [11].  
 HIV is a blood-borne retrovirus that is predominantly transmitted through 
sexual contact, via percutaneous and prenatal routes [12-16]. The risk of HIV 
infection is dependent on the type of exposure or behavior and can range from a 
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CDC estimated Per-Act Probability of 9,250/10,000 for blood transfusions, 
63/10,000 for needle sharing injection drug use, 138/10,000 for receptive anal 
intercourse, and 8/10,000 receptive penile-vaginal intercourse [17]. HIV infection 
disproportionally affects men who have sex with men (MSM), transgender 
individuals, sex workers, and injection drug users. In the United States of 
America, homosexual and bisexual men account for an estimated 83% while 
heterosexual contact accounts for an estimated 24% HIV diagnosis in 2014. 
 
HIV Phylogeny 
 
 Two types of HIV can lead to a productive infection in humans: human 
immunodeficiency virus type 1 (HIV-1) and human immunodeficiency virus type 2 
(HIV-2). Although, both strains share similarities in the genome arrangement, 
routes of transmission, replication life cycle, and clinical disease, HIV-2 has a 
lower transmissibility, pathogenicity and is mainly confined to West Africa [18, 
19]. 
 Several factors that contribute to the high genetic variability of HIV-1 
include the error-prone reverse transcriptase and lack of nucleic acid 
proofreading [20], high viral turnover rate in vivo [21], host selective immune 
pressures [22], and viral recombination [23]. HIV-1 is categorized into three major 
phylogenetic groups based on viral sequence homology, Major (M), Outlier (O), 
and Non-M/Non-O (N) [24, 25]. HIV-1 Group N infection has only been identified 
in Cameroon and Group O is endemic to West Africa [26, 27]. HIV-1 Group M 
represents the main global circulating virus and is subdivided into subtype clades 
(A, B, C, D, E, F, G, H, J, K, and circulating recombinant forms (CRF)) that are 
geographically distributed. Subtype C is responsible for the majority of HIV-1 
infection in parts of Africa, while Subtype B dominates infection in the Americas 
and Europe [28]. CRF arise from a recombination of multiple subtypes in a single 
infected person [29]. There has been a surge of CRF_AE infections due to an 
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increase in globalization and transportation seen in Thailand, Hong Kong, 
Malaysia and the Philippines [30]. The vast genetic diversity of HIV quasispecies 
has important implications in understanding host-viral evolution leading to better 
diagnostic testing, control of disease progression and therapeutic designs. 
 
*HIV-1 will be referred to as “HIV” unless noted otherwise. 
 
HIV Genome 
 
 HIV is a lentivirus that belongs to the Retroviridae family and is 
characterized to have a reverse transcription of its viral genome and subsequent 
integration into the host genome. The HIV viral genome consists of two copies of 
positive-sense, single-stranded RNA that is ~9kb in length, flanked by 5’ and 3’ 
long terminal repeats and encodes for structural (Gag, Env), enzyme (Pol), 
essential regulatory (Tat, Rev), and accessory (Nef, Vpu, Vpr, Vif) proteins 
required for host cell infection, immune evasion, and propagation of infectious 
virons [31].  
 The group-specific antigen gene (Gag) encodes Gag p55 protein that is 
cleaved to make up structural components of the matrix (p17), capsid (p24) and 
nucleocapsid (p7), and spacer (p6) [32]. The envelope (Env) gene encodes the 
transmembrane glycoproteins gp120 and gp41 that make up viral spikes on the 
surface of the mature viron and are required for host cell recognition, binding and 
fusion [32]. The polymerase (Pol) gene encodes enzymes protease (PR) 
required for cleavage of polyproteins during virus maturation, reverse 
transcriptase (RT) required for transcribing single-stranded viral RNA to double-
stranded viral DNA, and integrase (IN) that mediates HIV proviral insertion into 
the host genomic DNA [33-35]. Essential regulatory proteins are encoded by the 
transcriptional transactivator (Tat) gene, which initiates transcription of viral RNA 
while Rev increases nuclear export of viral mRNAs [36, 37]. The accessory 
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proteins Nef, Vpu and Vif encoded increase pathogenicity and immune evasion. 
Nef is one of the first viral proteins produced and has the ability to downregulate 
the expression of cluster of differentiation (CD) 4 and Human Leukocyte Antigen 
(HLA) Class I [38, 39]. The Vpu protein increases viral progeny release and is 
responsible for degrading CD4 in the cytoplasm [40]. The Vpr protein plays a role 
in forming the pre-integration complex (PIC) and facilitating nuclear import of the 
double stranded HIV DNA template in the absence of mitosis [41]. The Vif protein 
has co-evolved to overcome the antiviral host restriction factor APOBEC3G [42]. 
All together, the HIV genome encodes proteins required to produce infectious 
virons and maintain a persistent infection. 
 
HIV Structure 
 
 The HIV virion is approximately 120nm in diameter [43]. The viral RNA 
and enzymes (IN, RT) are enclosed by the viral capsid (p24) and matrix protein 
(p17) [44]. The core of the virus is surrounded by the matrix protein and is 
integrated into the external lipid bilayer envelope derived from the host cell [45]. 
The surface of the viron is covered in trimetric glycoprotein spikes, made of 
gp120 and gp41 that mediate viral tropisms and membrane fusion [46]. 
 
HIV Life Cycle 
 
 HIV replication can be divided into several steps that include entry, 
uncoating, reverse transcription, integration, transcription, translation, assembly, 
budding and maturation. HIV primarily targets host cells expressing the CD4 and 
CC-chemokine receptor 5 (CCR5) or CXC-chemokine receptor 4 (CXCR4) 
receptors namely CD4 T lymphocyte cells (CD4 T cell), macrophages and 
microglial cells [47]. Entry begins with the binding of gp120 to the CD4 receptor 
along with one co-receptor (CCR5 or CXCR4) resulting in a gp41 mediated 
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membrane fusion [43, 48]. The viral capsid is uncoated in the cytoplasm to 
release HIV RNA, enzymes and proteins [44]. HIV RNA is reverse transcribed by 
RT to produce a double-stranded HIV DNA template [34]. The lack of 
proofreading and the error-prone HIV RT promotes mutations (1/1700 error rate 
of incorporated nucleotide) resulting in the extremely high genetic variability of 
HIV [20, 49]. Vpr forms a nucleoprotein PIC that transports the pre-integrated 
HIV DNA into the nucleus [50]. The viral protein IN facilitates the integration of 
HIV DNA into the host chromosome [51]. This integrated HIV DNA, or provirus, 
can be transcribed as a cellular gene. The viral proteins Tat and Rev control the 
host transcriptional machinery to produce and export mRNA from the HIV 
provirus in an infected cell nucleus. Tat stimulates the transcription of the proviral 
5’LTR promoter region by directing cellular transcription elongation factor (P-
TEFb) to RNA polymerases [52]. HIV mRNA transcripts undergo splicing to 
produce a full range of mRNAs required to encode viral proteins [53]. Rev is 
responsible for exporting intron-containing viral mRNA out of the nucleus [54]. 
Translation of the HIV mRNA and protein synthesis occurs in the cytoplasm. Viral 
assembly happens near the plasma membrane to include all of the components 
required for infecting a new cell. Two copies of viral RNA and viral enzymes (PR, 
RT and IN) are packaged into the viral envelope and bud off of the host plasma 
membrane [55]. The Gag-Pol polyprotein is cleaved by the viral protease to 
produce a mature viron capable of infecting a new host cell [56]. 
 
HIV Infection and Disease Progression 
 
 HIV can be transmitted during sexual contact, from sharing intravenous 
needles, from blood transfusions, and mother-to-child [57]. Infectious virus is 
present in the plasma of blood, female genital secretions, and male seminal fluid 
[58, 59]. HIV acquisition through mucosal tissues is one of the leading causes of 
infection. At the site of infection, through micro-abrasions in the mucosa 
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epithelium, the virus gains access to tissue resident CD4 T cells and antigen 
presenting cells (APCs) to create a local focus of infection [60]. Tissue resident 
dendritic cells (DCs) are able to capture whole virus and facilitate trans-infection 
of CD4 T cells [61]. Infected CD4 T cells and APCs migrate to draining lymph 
nodes and eventually distal lymph nodes along with other tissues within two 
weeks of infection. The follicular dendritic network is able to retain infectious virus 
within immune privileged B cell follicles contributing to lymph node fibrosis and 
improper reconstitution of CD4 T cells [62]. Furthermore, follicular CD4 T cells 
(Tfh) are the main source of virus during disease progression [63]. 
 HIV disease progression can be divided into an acute phase, chronic 
phase, and AIDS. The acute clinical manifestations include fever, generalized 
lymphadenopathy, nonspecific rash and malaise [64]. In the absence of 
combined antiretroviral therapy (cART), viral replication continues with a peak in 
plasma viremia to about 10^6 copies/mL at about 4 weeks after initial infection 
and slowly declines to a viral set point as the individual immune system begins to 
control the virus [65]. Concurrently, the CD4 T cells, which become infected with 
HIV, decline quickly from ~1000 cells/mL to ~500 cells/mL due to viral cytopathic 
effects (CPE), chronic inflammation, and adaptive immune killing [65]. The CD4 T 
cell nadir, the lowest ever CD4 Count, will establish an immunological set point 
that will determine how well CD4 T cell counts recover after acute infection [66]. 
The dynamics of acute HIV viremia and antibody seroconversion are categorized 
into Fiebig stages I-VI that are based on sequential gain in positive HIV clinical 
diagnostic tests starting with Fiebig I viral RNA by polymerase chain reaction 
(PCR), Fiebig II p24 and p31 enzyme-linked immunosorbent assay (ELISA), and 
Fiebig III-VI HIV-specific antibodies by ELISA and western blot [67, 68]. 
Currently, fourth generation immunoassays are redefining Fiebig stage I acute 
HIV infection into two groups with depending on the levels of HIV RNA and DNA 
[69]. Three-to-nine weeks after infection the CD8 T cell responses and anti-HIV 
antibody titers begin to rise and partially control virus replication [70, 71]. 
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Although, HIV-specific CD8 T cell responses are more effective than anti-HIV 
antibodies at controlling virally infected cells [72], both arms of the adaptive 
immune response contribute to the overall control of virus.  
 The chronic infection phase can last from one to twenty years with 
individuals experiencing little-to-no clinical symptoms, termed “clinical latency”. 
The virus slowly replicates throughout the body with a gradual loss of both 
circulating and tissue based CD4 T cells. The high density of CD4 T cells in gut 
associated lymphoid tissues (GALT) is most impacted. Depletion of GALT CD4 T 
cells leads to intestinal permeability and microbial translocation resulting in 
persistent peripheral immune activation [73]. HIV infection within the thymus 
contributes to CD4 T cell decline and regenerative failure [74]. Furthermore, HIV 
infection within secondary lymph nodes causes fibrosis and severely affects CD4 
T cells’ ability to survive and reconstitute the peripheral CD4 T cell population 
[62].  
 The AIDS phase is defined by the depletion of CD4 T cells to less than 
200 cells/ml in blood, increased plasma viremia and exhibitions of opportunistic 
infections or cancers that include pneumocystis, pneumonia, candidiasis, Kaposi 
sarcoma, and wasting syndrome. During the final phase, without treatment, 
individuals only survive for about 3 years [75]. 
 Disease progression rates vary depending on the infected individual. 
There is some evidence that host human leukocyte antigen (HLA) genetics, 
immune function, viral genetic variability, and co-infections may affect the 
progression rate to AIDS [76]. HIV infected individuals can be grouped based on 
their progression to AIDS. “Rapid progressors” have a fast decline in CD4 T cells 
and progress to AIDS within four years of primary HIV infection [76]. The majority 
of infected individuals are “intermediate progressors”, which have persistent 
detectable plasma viremia and slow decline in CD4 T cells and progress to AIDS 
within 6-10 years [75]. “Long-term non-progressors (LTNP)” are individuals that 
maintain a normal CD4 count (>500 cells/µl) with low detectable plasma viremia 
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(<10,000 viral copies/ml) for up to 10 years in the absence cART [77]. A small 
subset of individuals, “elite controllers”, are able to sustain spontaneous control 
of virus (<50 viral copies/ml) while maintaining normal CD4 counts in the 
absence of cART [78]. “Immunological non-responders (INR)” make up 30% of 
individuals on therapy, which fail to recover CD4 T cells (<500 cells/µl) despite 
achieving complete suppression of plasma viremia [79]. Each unique group of 
infected individuals has contributed to studies revealing novel and differential 
immune mechanisms driving HIV disease progression.  
 
HIV Diagnosis 
 
 Blood tests for HIV are the most common definitive way to diagnose HIV 
infection. These test include viral RNA (PCR), p24 (ELISA), HIV specific antibody 
(ELISA), and HIV specific antibody (western blot). The CDC recommends using a 
fourth generation antigen-antibody assay followed by an antibody assay that can 
differentiate between HIV-1 and HIV-2 as conformation [80]. 
 Rapid antibody tests can screen for HIV infection from a finger stick of 
blood or oral fluid within thirty minutes and is extremely useful in public testing 
bars, drop in clinics, or health fairs. However, the current rapid HIV tests have 
limited sensitivity in detecting HIV during an acute infection [81]. All rapid test 
results should be confirmed with an antigen-antibody assay. 
 The U.S. Preventative Services Task Force recommends that clinicians 
screen adolescents and adults (15-65 years) for HIV infection at least once, and 
every 3-6 months for individuals at risk [82]. Individuals at risk include male-to-
male sexual contact, injection drug use, anal or vaginal sex without condom use, 
and individuals who exchange drugs or money for sex. 
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Non-human primate model of HIV/AIDS 
 
 Animal models provide invaluable information in the search for an HIV 
cure. Non-human primates are the most physiologically relevant model to study 
HIV/AIDS and allows for invasive interrogation of the disease in cellular and 
anatomical compartments, study of host-viral interaction, analytical treatment 
interruption and pre-clinical drug or vaccine testing.  
 Simian immunodeficiency virus (SIV) and HIV share similarities in the viral 
genome, gene products, and structure. Over 40 species of African green 
monkeys, sooty mangabeys and mandrills are natural hosts for SIV. Upon acute 
infection, the natural hosts have high levels of sustained plasma viremia, rapid T 
cell turnover and activation of innate and adaptive immunity [83]. However, the 
SIV infection does not result in chronic immune activation, depletion of peripheral 
CD4 T cells, or destruction of lymph node architecture [83]. As is observed in 
HIV, non-natural hosts, such as Rhesus macaques (RM) (Macaca mulatta), more 
closely resemble HIV pathogenesis. The commonly used strains of macaque-
adapted SIV (SIVmac239, SIVmac251, or chimeric simian/human 
immunodeficiency virus (SHIV)) have been used to experimentally challenge 
RMs [84]. A single dose challenge, through intravenous or intrarectal route, is 
sufficient to establish a robust infection [85]. Similar to HIV infection, SIV-infected 
RMs experience ongoing plasma viral replication and depletion of peripheral and 
GALT CD4 T cells [85]. SIV disease progression is more rapid compared to HIV 
infection with SIV infected RMs showing AIDS-related illnesses within 2-3 years 
without therapeutic intervention. Similar to cART treatment for HIV-infected 
individuals, combinational antiretroviral therapy regimens consisting of four/five-
drugs can be administered orally or subcutaneously to persistently suppress 
plasma viral replication in SIV infected RMs, providing robust in vivo models for 
HIV persistence and innovative therapeutic curative strategies [86]. 
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HIV Pathogenesis 
 
 HIV infects a small portion of cells that make up the immune system, 
specifically cells that express CD4 cell surface receptor molecule and co-receptor 
C-C chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 
(CXCR4), this includes activated memory CD4 T cells [87], follicular helper CD4 
T cells [63], and cells of myeloid lineage [88]. During untreated pathogenic 
infection, direct and indirect effects, such as viral cytopathic effect and systemic 
chronic immune activation, drive CD4 T cell depletion in the peripheral blood and 
secondary lymphoid tissues leading to immune dysfunction and increased 
susceptibility to opportunistic infections and the onset of AIDS and death.  
 HIV-infected individuals classified by their disease progression provide 
insights into pathogenic HIV-associated immune activation. For instance, CD8 T 
cells from cART suppressed, chronically HIV-infected individuals express high 
levels of immune activation markers such as CD38 and HLA-DR as well as 
increased levels of proliferating T cells compared to HIV-uninfected individuals 
[89]. The activation of CD8 T cells shows a stronger correlation with decreased 
survival time than viral loads or CD4 counts [90]. Residual immune activation, in 
the absence of replicating virus in the plasma, correlates with increased morbidity 
and mortality [91]. HIV-infected individuals that are able to spontaneously control 
viral replication, “elite controllers”, show higher levels of immune activation 
compared to HIV-uninfected and cART suppressed individuals, and have a 
higher rate of developing HIV-related comorbidities [92]. HIV-infected “long-term 
non-progressors” display reduced levels of immune activation while maintaining 
CD4 T cell counts despite having high plasma viremia [93]. Finally, as previously 
mentioned, the non-human primate natural hosts to SIV have sustained plasma 
viremia and massive acute CD4 depletion, however they do not experience 
chronic immune activation and do not progress to AIDS. Reducing immune 
activation is an important component to HIV cure strategies. 
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Secondary lymphoid tissues, such as the gut mucosa, are largely affected by HIV 
infection and contribute to chronic HIV-associated immune activation. During 
acute HIV infection there is a massive depletion of CCR5 expressing CD4 T cells 
in the gut [94], including the CD4 T helper cells 17 (Th17), a subset which is 
crucial for maintenance of the mucosal intestinal barrier [95]. Compromised 
mucosal integrity along with the loss of intestinal epithelial cells and disruption of 
tight junctions result in microbial translocation and systemic bacteremia leading 
to persistent peripheral immune activation and inflammation [96]. A deeper 
understanding of immune function in the gut will be required to restore gut 
integrity and reduce immune activation during chronic HIV infection.  
 Lymph nodes are anatomical compartments that are responsible for 
generating effective immune responses [97], crucial for T cell homeostasis [98] 
and the main site for HIV replication and persistence [99-102]. Several functional 
and structural changes occur during pathogenic HIV infection. Follicular dendritic 
cells trap live virus and facilitate follicular helper CD4 T cell (Tfh) infection in 
germinal centers of lymph nodes [63, 103, 104]. Activated T regulatory cells 
(Tregs) produce TGF-β1 leading to collagen deposition [105] that damages the 
fibroblastic reticular cell (FRC) network [106]. This leads to decreased IL-7, an 
important cytokine in promoting naïve T cell survival, resulting in improper T cell 
hemostasis and impaired CD4 T cell reconstitution [106]. Additionally, the FRC 
remains damaged despite viral suppression during cART [106]. This vicious cycle 
of HIV replication and immune activation impacts cellular immune function and 
promotes viral persistence. Targeting HIV persistence in lymph node will need to 
be considered in future HIV cure strategies.  
 
Treatment and Prevention of HIV infection 
 
 With the advent of anti-retroviral (ARV) drugs, individuals infected with HIV 
are now living decades longer than before. There are currently five classes of 
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Food and Drug Administration (FDA)-approved ARV drugs available in the USA 
as follows: fusion inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors 
(N(t)RTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease 
inhibitors and integrase inhibitors. Each class of ARVs works by targeting a 
specific stage in the HIV life cycle that is crucial for producing replication 
competent viral progeny. As standard of care, cART is required to simultaneously 
suppress multiple steps of the HIV lifecycle to control viral replication and reduce 
drug resistance. cART consists of two N(t)RTIs plus (one NNRTI or 
protease/integrase inhibitors) [107]. Recent studies suggest that immediate 
initiation of cART, regardless of CD4 count, leads to better long-term immune 
consequences and public health benefits of reducing risk of transmission [108, 
109].  
 Despite the remarkable success of cART in controlling viral replication and 
reducing AIDS-related deaths, several drawbacks are associated with the lifelong 
therapy. The patient and doctor must consider toxicity, cost and adherence to 
drug regimens. Some factors that might be responsible for an individual failing to 
respond to treatment are non-adherence [110], drug resistance [111, 112], host 
genetic polymorphisms [113] and drug malabsorption [114]. HIV infected 
individuals in resource limited-countries, including Sub-Saharan Africa, have 
limited access to healthcare where cART may not be optimal. Moreover, cART 
fails to eradicate the viral reservoirs of the virus [115]. If cART is interrupted from 
an infected individual, the virus rapidly and robustly rebounds [116]. Furthermore, 
cART fails to restore complete immune health [117] with survival rates 
significantly reduced compared to HIV-uninfected individuals [118]. Moreover, 
cART does not fully reduce immune activation, which contributes to non-AIDS 
comorbidities such as cardiovascular disease, cancer, kidney disease, liver 
disease, neurological impairment, and bone diseases [117]. More effective 
therapies and strategies will be required to manage and eliminate HIV infection. 
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 No effective cure or vaccine exists. The recommended prevention of HIV 
infection is to avoid high-risk behavioral activities that include unprotected sex or 
sharing needles. Programs such as The Joint United Nations Program on 
HIV/AIDS (UNAIDS) aim to educate the community, break social stigma and 
increase awareness about HIV infection. The UNAIDS ambitious strategy to 
coordinate global action in response to the HIV/AIDS epidemic is to have 95% of 
all individuals know their HIV status, 95% of infected individuals on cART and 
95% of infected individuals with undetectable viral loads by 2030 [119].  
 ARVs can be used as powerful tools to potentially prevent HIV infection. 
Truvada, a combination of Tenofovir and Emtricitabine (both NRTIs), is the first 
FDA-approved ARV to be used as a daily pre-exposure prophylaxis (PrEP) to 
reduce HIV acquisition in at-risk populations. PrEP has been shown to be very 
effective in reducing sexual transmission when combined with risk-management 
counseling and condom use [116]. However, poor daily adherence is associated 
with decreased PrEP efficacy [116]. PrEP must be taken on a daily schedule to 
maintain optimal plasma drug consternations to prevent HIV acquisition. The two-
drug regimen combined with Lopinavir/Ritonavir can also be used as Post-
Exposure Prophylaxis (PEP) within 72 hours after a single high-risk HIV 
exposure [120]. The same two-drug backbone plus Efavirenz are used to prevent 
mother-to-child transmission by virally suppressing the HIV-infected mother 
before giving birth and during breast-feeding [120]. The effectiveness of ARV 
intervention will ultimately rely on community education and engagement, access 
to ARVs in resource-limited setting, and high level of compliance and adherence.  
 
HIV Vaccine Approaches 
 
 Vaccines are one of the best strategies to prime the immune system to 
produce durable long-lasting protection against infections. However, as of today, 
there are no effective vaccines that prevent HIV infection. Conventional efforts to 
generate an HIV vaccine have failed due to the genetic diversity of HIV, limited 
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correlates of vaccine protection, viral escape mutations, heavily glycosylated Env 
spikes and early viral integration into the host genome. An ideal HIV vaccine 
should elicit both humoral and cellular responses that generate sterilizing 
protection against HIV acquisition and establishment of the viral reservoir across 
multiple serotypes. 
 Six vaccine efficacy trials during 1987 – 2013 have all failed except one 
with modest efficacy. Of note, the 2007 STEP trial and 2013 HVTN trial used a 
replication-incompetent adenovirus type 5 (Ad5) vector containing HIV DNA Gag, 
Pol, and Nef to prime the immune system. Both trials were discontinued due to 
an increased HIV acquisition in the vaccinated arms [121, 122]. However, the 
first evidence that an HIV vaccine may be protective was observed in the RV144 
Thailand trial. The RV144 vaccine used a prime/boost strategy, individuals were 
“primed” with a replication-incompetent canarypox vector containing HIV DNA 
Env, Gag and Pro (ALVAC) and “boosted” with recombinant Env gp120 protein 
(AIDSVAX) in hopes of generating both humoral and cellular responses [123]. 
The results of the RV144 trial showed a modest vaccine efficacy of 31.2% at 42 
months [124]. Interestingly, Env mediated antibody-dependent cellular 
cytotoxicity (ADCC) against the gp120 variable loop 2 and T cell responses 
correlated with decreased HIV risk of infection suggesting that humoral and 
cellular components may be required for an effective HIV vaccine [124]. Building 
off these results, a new vaccine clinical trial (HVTN 702) is scheduled to 
commence in South Africa in 2017. The HVTN 702 vaccine candidate is based 
on the RV144 ALVAC/AIDSVAX vaccine with modified components and 
vaccination regimen designed to increase the magnitude and duration of 
protective humoral and cellular immune responses.  
 Several research groups have identified antibodies from HIV-infected 
individuals that have the ability to neutralize a diverse pool of HIV isolates. These 
broadly neutralizing antibodies (bnAb) have been characterized to target five 
different sites on the HIV Env trimer: the CD4 binding site (CD4bs), the V3 and 
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V1V2-glycan sites, gp120-gp41 sites and the gp41 membrane proximal external 
region (MPER) [125, 126]. Passive administration of the bnAb PGT121, targeting 
the V3 glycan-binding site, to SHIV infected RMs resulted in viral control with no 
antibody neutralization escape in a several infected animals [127]. In a small 
clinical trial, passive administration of CD4bs bnAb 3BNC117 to HIV-infected 
individuals was able to suppress plasma viremia for four-weeks, however an 
emergence of resistant viral strains were observed [128]. Comparably, 
administration of CD4bs bnAb VRC01 resulted in an eight-week delay in viral 
rebound after analytical treatment interruption [129]. These data suggest that 
passive bnAb therapy may be an important component to HIV eradication 
strategies and vaccines. The next-generation of bnAbs are being modified in vitro 
to increase breadth, potency and serum half-lives [130, 131]. Nonetheless, a 
deeper understanding is required to identify preferential structures, 
conformations and sequences of Env immunogens that can induce bnAbs as an 
HIV vaccine. 
 In recent novel non-human primate vaccination studies, rhesus macaques 
(RMs) vaccinated with rhesus cytomegalovirus (rhCMV) vector expressing SIV 
proteins (rhCMV/SIV) were protected against repeated SIVmac239 challenge in 
approximately 50% of RMs [132, 133]. The rhCMV/SIV vaccine was later found 
to induce broad, diverse MHC-E restricted SIV-specific CD8 T cell responses that 
were able to clear pathogenic SIV infection [134]. These data suggests that 
lentiviral reservoirs are susceptible to antiviral CD8 T cell mediated cellular 
immunity. Future studies will be required to determine if similar immune 
responses can be recapitulated in humans. 
 Novel vaccine strategies should be a two-pronged approach. The first 
should focus on sequential rounds of engineered Env immunogens to induce 
potent bnAbs that can block or reduce acquisition of HIV infection. The second 
should potentially use a CMV-based vector to induce broad cellular responses to 
control breakthrough infections. Furthermore, the immune response should be 
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long lasting and able to block multiple routes of infections across global HIV 
serotypes.  
 
HIV Reservoirs 
 
 Despite therapeutic advances, the main obstacle to eliminating virus from 
cART suppressed HIV-infected individuals are HIV reservoirs that harbor 
replication competent virus driven by T cell survival and homeostatic proliferation 
[135]. There have been several cellular (CD4 T cells, macrophages, follicular 
dendritic cells) and anatomical (brain, gut, male urogenital tract, lymph nodes) 
reservoirs described [136]. RM studies suggest that SIV reservoirs, able to 
sustain a productive infection, are seeded as early as three days post-infection 
[137]. HIV can establish a reversibly nonproductive infection in CD4 T cells 
termed “latency” [138]. Latently infected cells contain a copy of the HIV provirus, 
however they do not transcribe HIV or produce any viral proteins, thus making 
them invisible to recognition by the immune system and resistant to cART [139]. 
Moreover, the half-life of the latent reservoir is estimated to be 44 months, 
suggesting it would take 73.4 years to eliminate one million latent cells on 
suppressive cART [140]. Identifying latent cells that harbor HIV provirus has 
been pursued with great interest with one study suggesting that CD32a marks 
CD4 T cells harboring replication competent provirus [141]. Several mechanisms 
that contribute to the transcriptional silencing of HIV include sequestration of host 
transcriptional factors, epigenetic silencing, transcriptional interference, and 
inhibition of RNA polymerase II [139]. The majority of latently infected cells reside 
in anatomical sanctuaries where cART concentrations may not be optimal. These 
sites include the lymph node [63] and gut associated lymphoid tissue (GALT) 
[142] and serve as the main source for HIV replication and production [143]. 
Future HIV cure strategies should focus on targeting latently infected cells and 
anatomical sites to disrupt and eliminate viral reservoirs. 
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Microbiota 
 
 There is an estimated ten trillion bacteria that live on and in the human 
body in symbiosis [144]. A majority of the commensal bacteria is focused in the 
gastrointestinal tract and play intricate roles in the development and function of 
the systemic immune system [145, 146]. The evidence of immune mediated 
diseases such as Chron’s disease, asthmas, diabetes, in addition to multiple 
sclerosis have been implicated with an alter microbial composition [147, 148]. 
Furthermore, the impact of microbiota-derived factors on the immune 
development is observed in specific-pathogen free mice, they develop significant 
differences in their immune cellular composition at mucosal sites [146]. Altering 
the microbial composition with fecal microbiota transplantation is an established 
way to treat Clostridium difficile [149]. However, to completely change the 
microbiota after neonatal establishment seems to be extremely difficult [150]. A 
better understanding of the mechanisms driving microbiota reconstitution along 
with the host-microbial immunological relationship is warranted. 
 During HIV infection, the gut is one of the earliest targeted sites of 
infection, it contains a high concentration of CCR5-expressing T cells resulting in 
CD4 T cell depletion and impaired immune reconstitution [151, 152]. Massive 
viral replication in the gut leads to the destruction of the epithelial barrier, 
indirectly leading to microbial translocation and altered community composition 
[73, 153]. Moreover, the early initiation of cART only partially restores gut 
mucosa integrity [154]. A better understanding of the roll the gut microbial 
composition plays during cART-suppressed HIV infection will help to inform 
future HIV cure strategies. 
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Introduction to Adaptive Immunity 
 
 The mammalian immune system plays an essential role in defending 
against pathogens and cancers. The immune response can be divided into two 
arms: innate and adaptive immunity. The innate immune system is composed of 
immune cells and complement proteins that can recognize and respond rapidly to 
nonspecific antigens [155]. Initial inflammation is generated by tissue resident 
innate immune cells (macrophages, neutrophils, dendritic cells (DCs), natural 
killer (NK) cells etc.) to prevent the spread of infection, promote tissue 
regeneration and recruit additional immune cells to initiate the expansion and 
differentiation of the adaptive immune response [155]. The adaptive immune 
system responds ~7-15 days after the initial antigen stimulation. Cell-mediated 
and antibody responses are produced by activated T cells and B cells, 
respectively. Antigens are processed into peptides and presented by major 
histocompatibility complexes (MHC) (known as human leukocyte antigens (HLA) 
in humans) to activate T cells. Three signals are required for T cell activation. 
First, antigen presenting cells (APCs) display peptide fragments restricted by 
HLA class I (HLA-A, HLA-B, HLA-C) to naïve CD8 T cells or by HLA Class II 
(HLA-DR, HLA-DP, HLA-DQ) to naïve CD4 T cells. Second, a positive co-
stimulation signal by CD28 T cell surface receptors to the B7 ligand is expressed 
on APCs. Third, cytokines are required to regulate the magnitude and duration of 
the immune response. Naïve CD8 T cells differentiate into effector cytotoxic CD8 
T cells that are capable of killing infected cells presenting antigen specific to its T 
cell receptor. Conversely, activated helper CD4 T cells interact with B cells to 
promote clonal expansion and antibody production. T cell and humoral mediated 
immunity are responsible for clearing the antigen and providing immunological 
memory for a faster more efficient response to the same antigen in future 
encounters [155].  
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T cell development 
 
 T cells are a type of lymphocytes that play an essential role in adaptive 
cell mediated immunity. They arise from hematopoietic stem cells from the bone 
marrow that migrate to the thymus where they undergo maturation and become 
immature thymocytes. These immature thymocytes, that do not express CD4 or 
CD8 (double-negative), undergo T cell receptor (TCR) germline DNA V(D)J 
recombination which contributes to the enormous T cell diversity [155]. The 
double-negative thymocytes go on to simultaneously express both CD4 and CD8 
(double-positive) and go through a “positive selection” process that ensures the 
TCR is able to recognize self-HLA molecules. Successful selection (not too 
strong or too weak) results in survival signals and expression of either CD4 or 
CD8 (single-positive) [155]. A “negative selection” process follows to remove any 
thymocytes that react with self-derived peptides [155]. Single positive thymocytes 
that have successful TCR recombination capable of recognizing peptide-HLA 
complexes with the correct affinity exit the thymus as naïve T cells ready to 
interact with cognate antigen peptides presented by APCs. 
 
CD8 T cells in HIV infection 
 
 Cytotoxic “Killer” CD8 T cells are one of the main cellular components of 
the adaptive immune system. Their TCR is capable of recognizing specific 
antigenic peptides presented by HLA-I complexes on infected cells while 
minimizing nonspecific bystander tissue damage. Priming of naïve CD8 T cells in 
secondary lymphoid organs by APCs results in differentiation and proliferation of 
antigen-experienced effector CD8 T cells [156]. At the peak of the primary 
response, effector CD8 T cells recognize infected cells, form an immunological 
synapse, and produce a variety of cytokines (interferon gamma, tumor necrosis 
factor alpha, interlukin-2, interlukin-4) [157] in addition to releasing cytotoxic lytic 
granules containing perforin and granzymes [158] resulting in cell lysis or 
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apoptosis. Alternatively, CD8 T cells can induce apoptosis by engaging death-
inducing receptors on infected cells [159]. During immune contraction, after the 
infection is cleared, a portion of antigen-induced effector CD8 T cells revert to a 
long-lived memory state capable of responding rapidly to similar antigens in 
future encounters [160]. 
 CD8 T cells play an important role in influencing the outcome of HIV 
infection. Several lines of evidence suggest CD8 T cells are responsible for the 
control of HIV replication during the clinical latency phase of chronic HIV 
infection. Gag-specific CD8 T cells are able to recognize HIV infected cells 
before viral integration and viral protein production [161]. The emergence of HIV-
specific CD8 T cells is associated with the post-peak decline of plasma viremia 
[162, 163]. Individuals with peptides restricted by specific HLA-I allele (HLA-B*57 
and HLA-B*27) elicit a greater CD8 T cell response and have decreased disease 
progression to AIDS [164, 165], with similar observations reported in SIV infected 
RMs with Mamu-B*08 and Mamu-B*17 [166, 167]. “Elite controllers” exhibit 
greater CD8 T cell polyfunctionality and in vitro killing [168, 169]. Additionally, 
when CD8 T cells are depleted from SIV infected RM on suppressive cART, 
there is an increase of plasma viremia, which becomes controlled upon CD8 T 
cell reconstitution, suggesting that CD8 T cells contribute to the control of 
HIV/SIV replication during suppressive cART [170]. However, despite the 
compelling evidence, CD8 T cells fail to clear the infection in a majority of HIV 
infected individuals. 
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CD8 T cell Dysfunction in HIV Infection 
 
 During unresolved chronic viral infections and cancers, low levels of 
persistent antigen and immune inflammation cause the impairment of antigen-
specific CD8 T cells, termed “T cell exhaustion” (Figure 1.1) [2, 171]. The 
Fig.1.1 T cell exhaustion. Clearance of acute infection results in a highly 
polyfunctional population of memory CD8 T cells able to quickly respond to 
similar future antigens. However, persistent antigen and inflammation results in 
a loss of polyfunctional CD8 T cells associated with the simultaneous 
expression of negative immune checkpoint receptors. Figure adapted from [2]. 
Reprinted with permission. 
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concept of CD8 T cell exhaustion was originally defined in the chronic 
lymphocytic choriomeningitis virus (LCMV) murine model. During the course of 
chronic LCMV infection, virus-specific CD8 T cells were activated but failed to 
produce any antiviral effector functions [172]. T cell exhaustion was later defined 
as having a progressive loss of polyfunctionality, starting with decreased 
interleukin 2 (IL-2) and tumor necrosis factor alpha (TNFα) production, leading to 
diminished proliferative and cytotoxic capacity and ultimately lacking the ability to 
produce large amounts of interferon gamma (IFN-γ) [173]. Concurrently, immune 
regulation contributes to T cell exhaustion, where there is a stepwise 
upregulation of negative immune checkpoint receptors (NCRs) at the cell surface 
of exhausted T cells that actively inhibit immune functions [173]. NCR pathways 
are an important immune “check-and-balance system” for maintaining self-
tolerance and prevention of autoimmunity [174]. A key feature of T cell 
exhaustion is the simultaneous expression of multiple NCRs on T cells, such as 
programmed death 1 (PD-1), T cell immunoglobulin mucin-domain 3 (TIM-3), 
lymphocyte activation gene 3 (Lag-3), Cytotoxic T- Lymphocyte associated 
protein 4 (CTLA-4), CD244, CD160 and others [171, 175]. The overexpression of 
these NCRs effectively dampens the T cell effector responses, ultimately 
resulting in the inability to control or eliminate chronic viral infections and 
cancers. 
 Increased expression of NCRs on viral-specific CD8 T cells such as PD-1, 
TIM-3 and LAG-3 during chronic HIV/SIV infection is associated with increased 
viral loads and accelerated disease progression [176-180]. Because NCR 
signaling is initiated by ligand-receptor interactions, they are susceptible to 
disruption by antibodies or recombinant forms of the ligands or receptors. 
Blocking these pathways with monoclonal antibodies has shown to restore viral-
specific T cell effector functions in vitro [176, 178-180]. Targeting multiple 
pathways has shown to synergistically improve antiviral T cell effector functions, 
implying that the NCR pathways are non-redundant and functionally independent 
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[179, 181]. Blocking the PD-1 pathway has been shown to reinvigorate SIV-
specific CD8 T cells and reduce plasma viremia while delaying viral rebound after 
cART interruption in vivo [182, 183]. Interestingly, targeting these pathways such 
as PD-1 and CTLA-4 has shown clinical benefit in cancers, generating durable 
responses and progression-free survival [184]. However, only a subset of 
individuals respond to treatment, suggesting additional mechanisms may be 
limiting the immune response [184]. Identifying additional NCR pathways during 
chronic HIV/SIV infection will inform interventions to restore T cell exhaustion and 
better control or clear the viral infection. 
 
HIV Cure and Sustainable Remission Strategies 
 
 The “Berlin Patient”, is the only individual who has been cured of HIV to 
date. He was infected with HIV for 11 years and on stable cART when he 
developed acute myeloid leukemia for which he received two sequential bone 
marrow transplants from donors with a mutant CCR5 (CCR5Δ32) gene [185]. 
Individuals with a homozygous CCR5Δ32 allele have been reported to be 
resistant to M-tropic HIV strains [186]. Remarkably, after the transplants when he 
stopped cART, the virus did not rebound nor could any virus be detected in his 
blood or tissues [185, 187]. Unfortunately, when similar hematopoietic stem cell 
transplantations were performed in two other HIV infected individuals, known as 
“The Boston Patients”, the virus rebounded several months after analytical 
treatment interruption [188]. Ultimately, this procedure has a high risk of 
comorbid complications and may not feasible to scale up as a global HIV cure. 
 Several innovative approaches have been proposed to target the viral 
reservoir. Multiple groups are developing gene-editing and cell-based therapies 
to target the viral reservoir. Gene-editing with CRISPR/Cas9, zinc-finger 
nucleases or transcription activator-like effector nucleases (TALEN) systems can 
disrupt CCR5 or CXCR4 expression, potentially protecting cells from infection 
	 25	
[189-191]. Using a similar gene-editing technique, Kaminski and colleagues were 
able to excise the entire HIV proviral genome from latently infected T cells in vivo 
in mice [192]. Another group has engineered anti-HIV chimeric antigen receptor 
(CAR) T cells based on bnAbs that can recognize and kill infected cells in vitro 
[193]. It has also been suggested to transcriptionally lock the virus into a “deep 
latency” with gene silencing or pharmacological agents to prevent reactivation 
after analytical treatment interruption [194-196]. Nonetheless, further studies will 
be required to deliver these systems in vivo and translate theses approaches into 
clinical applications. 
 One HIV cure strategy of interest is the “shock and kill” approach, which 
involves flushing out virus and eliminating infected cells (Figure 1.2). Latency-
reversing agents (LRAs) are used to reactivate cells harboring latent virus 
(shock), then in combination with cART, the immune system will be able to 
recognize and eliminate the infected cells (kill) [1].  
 The LRAs are classified into groups based on their mechanism of 
reactivation. LRAs include protein kinase C (PKC) agonists, histone deacetylase 
inhibitors (HDACi), histone methylation inhibitors (HMTi), DNA methyltransferase 
inhibitors (DNMTi), inhibitors of bromodomain and extra-terminal proteins (BET), 
Toll-like receptor agonist, retinoic acid-inducible gene I (RIG-I) agonist, immune 
checkpoint blockade and unclassified agents such as disulfiram [197-200]. 
Several small clinical trials have assessed the ability of these LRAs to reactivate 
viral production from the stable latent reservoir in vivo, however there was little 
impact on the size of the viral reservoir [201-206], suggesting additional immune 
mechanisms may be required for elimination of reactivated latently infected cells. 
A combination of attack plans will most likely be required to impact viral 
persistence while improving immune function to eliminate or control viral 
infection. 
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Fig.1.2 “Shock and Kill” HIV Cure strategy. Figure represents the HIV cure 
strategy to flush out latent HIV and eliminate infected cells while protecting 
new cells from being infected with cART. Figure adapted from [1].  
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CHAPTER 2 
DISSERTATION SCOPE 
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Background for research questions 
 
 HIV infection remains a global health concern with an estimated 36.9 
million individuals living with HIV and a total of 39 million HIV related deaths at 
the end of 2015. Despite therapeutic advances an effective HIV cure or vaccine 
does not exist. Current combinational antiretroviral therapy is able to suppress 
plasma viremia to undetectable levels, however it fails to target the integrated 
provirus and eradicate the infection. As a result, HIV infected individuals must 
adhere to therapy for life at a significant finical cost and potential long-term side 
effects. 
 In the absence of treatment, HIV infection is brought partially under control 
by the infected person’s immune system, specifically by an immune system cell 
called a cytotoxic “killer” CD8 T cell. The response of these cells and HIV during 
the early stages of infection is crucial and will determine how the disease will 
progress. Over time, the immune damage mediated by HIV infection affects the 
function of the CD8 T cell even if with the addition of combination antiretroviral 
therapy (cART).  
 During unresolved chronic HIV infection, low levels of persistent antigen 
and immune inflammation cause viral specific CD8 T cells to become impaired 
and unable to eliminate virally infected cells. CD8 T cells begin to coordinately 
upregulate a series of negative checkpoint receptors (NCR) that increases the 
threshold necessary for activation. PD-1 is an early NCR associated with loss of 
proliferative capacity, while TIM-3 marks a more dysfunctional subset with 
diminished proliferative and cytokine capacity. Interfering with these NCR 
pathways alone or in combination has shown to restore cytoxicity and increased 
suppression of HIV infected CD4 T cells, however not all properties of exhausted 
cells are restored, implying that these pathways are non-redundant mechanisms 
of maintaining immune tolerance. Furthermore, adaptive resistance to PD-1 
blockade has shown upregulation of alternative NCRs to compensate against 
	 29	
single blockade, identifying additional NCRs is imperative to developing novel 
therapies to restore immune functions.  
 A recently described NCR, T cell immunoreceptor with immunoglobulin 
and ITIM domains (TIGIT: also known as Vsig9, Vstm3 or WUCAM), has shown 
to be expressed on CD8 T cells and NK Cells and has indirect and direct 
inhibitory effects. Exploration of TIGIT and other NCRs during HIV infection is 
critical to identifying novel immune pathways as targets to restore immune 
function and control or eliminate the virus. 
 
Long-term goal and Objectives 
 
 Our long-term goal is to understand mechanisms driving immune 
dysfunction that mediate the HIV disease progression and develop effective 
immune-based therapies for prevention or eradication of HIV infection. 
 To accomplish the objectives of this study, cutting edge 
immunophenotyping, immune pathway blockades, multiplex assays, genetic 
analysis and bioinformatics were employed to assess the role of TIGIT in HIV 
and SIV infection to identify immune pathways that can be targeted during cART 
suppressed HIV/SIV infection.  
 We hypothesize that HIV/SIV infection will result in an expansion of 
TIGIT+ T cells that which contributes to immune dysfunction, furthermore 
targeting the TIGIT pathway with novel targeted reagents will restore effector 
functions and contribute to the clearance of HIV infected cells. 
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Aims 
 
Paper I: To investigate the role of TIGIT on CD8 and CD4 T cells in HIV and SIV 
infection and the relationship with disease progression and viral persistence. 
 
Paper II in preparation: To explore the role of TIGIT and TIGIT Ligands in the 
blood and tissues during cART suppressed HIV infection. 
 
Significance 
 
 The proposed research is an innovative approach to identify and 
characterize multiple immune pathways that can be potentially targeted to 
increase the immune capacity to eliminate infected cells during HIV infection. HIV 
infection remains a global health concern for which there is no effective cure or 
vaccine. Individuals on suppressive cART have increased non-AIDS 
comorbidities, decreased life expectancy and significant economic strain 
compared to HIV-uninfected population controls. The results from this study can 
be applied to “shock and kill” strategies currently being evaluated to eradicate 
HIV infection in vivo. This study will provide insight into immune dysfunction and 
HIV persistence, which will have a significant impact in the development of 
targeted therapeutics to enhance anti-HIV immunity. 
  
	 31	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
TIGIT MARKS EXHAUSTED T CELLS, CORRELATES WITH DISEASE 
PROGRESSION AND SERVES AS A TARGET FOR IMMUNE RESTORATION 
IN HIV AND SIV INFECTION 
 
Chew et. al. PLoS Pathogens 2016 Jan 7;12(1):e1005349 
 
*Originally published in the Peer Review Journal PLoS Pathogens. Chew GM, 
Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. (2016) TIGIT Marks 
Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target 
for Immune Restoration in HIV and SIV Infection. PLoS Pathogens 12(1): 
e1005349. doi:10.1371/journal.ppat.1005349 
 
  
	 32	
TIGIT Marks Exhausted T cells, Correlates with Disease Progression, and 
Serves as a Target for Immune Restoration in HIV and SIV Infection 
 
Glen M. Chew1, Tsuyoshi Fujita1,2, Gabriela M. Webb3,4, Benjamin J. Burwitz3,4, 
Helen L. Wu3,4, Jason S. Reed3,4, Katherine B. Hammond3,4, Kiera L. Clayton5, 
Naoto Ishii2, Mohamed Abdel-Mohsen6, Teri Liegler6, Brooks I. Mitchell1, 
Frederick M. Hecht7, Mario Ostrowski5, Cecilia M. Shikuma1, Scott G. Hansen3,4, 
Mark Maurer8, Alan J. Korman8, Steven G. Deeks7, Jonah B. Sacha3,4* and 
Lishomwa C. Ndhlovu1* 
 
1Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns 
School of Medicine, University of Hawaii, Honolulu, HI 96813, USA; 2Department 
of Microbiology and Immunology, Tohoku University Graduate School of 
Medicine, Sendai 980- 8575, Japan; 3Vaccine & Gene Therapy Institute and 
4Oregon National Primate Research Center, Oregon Health & Science University, 
Portland, OR 97006, USA; 5Department of Immunology, University of Toronto, 
Toronto, Ontario M5S 1A8, Canada; 6Division of Experimental Medicine and 
7HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, 
University of California, San Francisco, CA 94110, USA; 8Biologics Discovery 
California, Bristol-Myers Squibb, Redwood City, CA 94063, USA.  
 
SHORT TITLE: Targeting TIGIT enhances HIV/SIV T cell immunity 
*JBS and LCN share equal Co-senior Authorship 
 
CORRESPONDING AUTHOR: Lishomwa C. Ndhlovu, MD, PhD, Hawaii Center 
for HIV/AIDS, John A. Burns School of Medicine, University of Hawaii, 651 Ilalo 
Street, Honolulu, HI, 96813, USA. Email: lndhlovu@hawaii.edu  
Keywords: HIV, TIGIT, PD-L1, Activation, CD8 T cells, CD4 T cells, Viral Load  
	 33	
SPECIFIC AIMS 
 
Specific Aim I: Determine the role of TIGIT on T cells during progressive 
HIV infection 
 A: To evaluate the expression of TIGIT on CD8 and CD4 T cells 
 during HIV infection 
 Hypothesis: TIGIT expression will be elevated on T cells during chronic 
 HIV infection. 
 Rationale: Chronic antigen exposure and persistent inflammation leads to 
 an increase of other negative checkpoint receptor expressions (TIM-3, 
 PD-1, LAG-3). 
 B: To determine the role of TIGIT and T cell dysfunction during HIV 
 infection 
 Hypothesis: T cells expressing TIGIT will have impaired effector function. 
 Rationale: Engagement of TIGIT results in blunted T cell functions, such 
 as proliferation, cytotoxicity and production of cytokines. 
 C: To determine the relation of CD4 T cells expressing TIGIT and the 
 CD4 viral reservoir 
 Hypothesis: CD4 T cells expressing TIGIT will be enriched for HIV DNA. 
 Rationale: Negative checkpoint receptors inhibit T cell activation, which 
 will prevent viral transcription and may be involved in maintaining the viral 
 reservoir. 
 
Aim II: Assess the role of TIGIT in the physiologically relevant non-human 
primate model of HIV/AIDS 
 A: Evaluate the expression of TIGIT in Rhesus macaques during 
 SIV infection 
 Hypothesis: Rhesus macaques will have an increased expression of 
 rhesus TIGIT (rhTIGIT) during SIV infection. 
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 Rationale: Non-human primates are close genetic relatives of humans and 
 when infected with SIV lead to AIDS-like diseases, mimicking HIV disease 
 progression and immune exhaustion. 
 B: Determine the role of rhesus TIGIT and T cell dysfunction during 
 SIV infection 
 Hypothesis: T cells expressing rhTIGIT will have impaired effector 
 functions. 
 Rationale: Engagement of negative checkpoint receptors on T cells results 
 in blunting T cell functions such as proliferation, cytotoxicity and 
 production of cytokines. 
 
Aim III: Determine the effects of blocking the TIGIT pathway on 
reinvigorating existing T cell effector functions during HIV/SIV infection 
 A: Test the activity of blocking human and rhesus TIGIT with  
 monoclonal antibodies 
 Hypothesis: Blocking the TIGIT pathway will increase pre-existing T cell 
 effector function in response to HIV/SIV antigens. 
 Rationale: Preventing engagement of other negative checkpoint 
 receptors results in improved T cell functions. 
 B: Determine the synergistic effects of simultaneously blocking 
 multiple NCR pathways reinvigorating existing T cell effector 
 functions 
 Hypothesis: Blocking multiple negative checkpoint receptor pathways will 
 lead to a greater increase of anti-HIV/SIV T cell functions compared to 
 single blockade alone. 
 Rationale: Preventing engagement of multiple negative checkpoint 
 receptors results in synergistic enhancement of T cell effector functions. 
 
  
	 35	
ABSTRACT 
 
 HIV infection induces phenotypic and functional changes to CD8 T cells 
defined by the coordinated upregulation of a series of negative checkpoint 
receptors that eventually result in T cell exhaustion and failure to control viral 
replication. We report that effector CD8 T cells during HIV infection in blood and 
SIV infection in lymphoid tissue exhibit higher levels of the negative checkpoint 
receptor TIGIT. Increased frequencies of TIGIT+ and TIGIT+ PD-1+ CD8 T cells 
correlated with parameters of HIV and SIV disease progression. TIGIT remained 
elevated despite viral suppression in those with either pharmacological 
antiretroviral control or immunologically in elite controllers. HIV and SIV-specific 
CD8 T cells were dysfunctional and expressed high levels of TIGIT and PD-1. 
Ex-vivo single or combinational antibody blockade of TIGIT and/or PD-L1 
restored viral-specific CD8 T cell effector responses. The frequency of TIGIT+ 
CD4 T cells correlated with the CD4 T cell total HIV DNA. These findings identify 
TIGIT as a novel marker of dysfunctional HIV-specific T cells and suggest TIGIT 
along with other checkpoint receptors may be novel curative HIV targets to 
reverse T cell exhaustion.  
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INTRODUCTION 
 
  During chronic viral infections, high antigenic loads continually stimulate T 
cells leading to progressive loss of function termed “T cell exhaustion” [2]. 
Throughout this period, T cells increase expression of several inhibitory immune 
receptors that raise the threshold for activation, resulting in suppressed immune 
responses. While Programmed Death Receptor-1 (PD-1) was one of the earliest 
surface markers of immune exhaustion identified [176, 177, 180, 182, 207, 208], 
we have shown that the surface glycoprotein, T cell immunoglobulin- and mucin 
domain-containing molecule (Tim)-3, defines a state of T cell exhaustion with 
diminished proliferative and cytokine capacities in chronic viral infection [178, 
209]. Thus, the upregulation of these and other negative checkpoints receptors 
may serve as potential targets for the reversal of T cell exhaustion. 
Indeed, blocking the interaction of T cell negative checkpoint receptor 
pathways using targeted reagents against PD-1/Programmed Death-Ligand 1 
(PD-L1), Tim-3, Lymphocyte-activation gene 3 (Lag-3) and CD160 has shown 
promise in reversing CD8 T cell exhaustion [178, 181, 182, 210, 211]. Reagents 
targeting many of these receptors are rapidly advancing in the clinic and are 
showing efficacy in the control of viral infectious disease [212] as well as anti-
tumor immunity [213-218]. A single dose of an antibody against PD-1 led to 
sustained clearance of hepatitis C virus infection in a small subset of individuals 
[212]. Blockade of the PD-1/PD-L1 axis in vivo demonstrated efficacy in restoring 
simian immunodeficiency virus (SIV)-specific T cell and humoral immunity, and 
led to a reduction of SIV viremia and in immune activation. However, this did not 
completely control virus, suggesting that additional therapies are needed. 
Importantly, not all features of the exhausted T-cells are restored by interfering 
with a single pathway [177, 178, 180, 207, 219]. Synergistic simultaneous dual 
blockade has yielded more promising responses suggesting these co-inhibitory 
molecules are non-redundant [179, 181, 218, 220].  
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T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) is a 
recently described immune checkpoint receptor that belongs to the CD28 family 
and contains an extracellular IgV domain, a transmembrane domain, and a 
cytoplasmic tail containing two-immunoreceptor tyrosine-based inhibitory motif 
(ITIM) [221]. It has been reported to be expressed on natural killer (NK) cells, 
CD8 and CD4 T cell subsets [221] and is induced upon activation [221-225]. 
TIGIT competes with DNAM-1, a co-stimulatory molecule, and TACTILE, a co-
inhibitory molecule, for the poliovirus receptor (PVR) a member of the nectin 
family of adhesion molecules that is expressed on dendritic cells (DCs) [221, 
222, 226]. Several murine and human studies strongly suggest that TIGIT is a 
negative modulator of T cell and NK cell function [223, 227-229]. A number of 
plausible mechanisms exist by which TIGIT can mediate inhibition of T and NK 
cell activation. Signaling through the TIGIT/PVR pathway with the standard 
recruitment of phosphatases via the intracellular ITIM domain of TIGIT can curtail 
T cell and NK cell responses [224]. This interaction has been shown to induce 
tolerogenic DCs to release the immunosuppressive cytokine IL-10 [223, 229]. 
Furthermore, disruption of DNAM-1 homodimerization by TIGIT can abrogate the 
positive co-stimulatory signals required for activation [217]. Recently, potent anti-
viral and anti-tumor responses related to enhanced CD8 T cell effector activity 
were generated following synergistic dual blockade of PD-L1 and TIGIT in the 
mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection 
[217] and ex-vivo in patients with advanced melanoma [230]. 
To date, these results have not been replicated in any human viral 
disease, but overexpression of both TIGIT and PD-1 on virally exhausted T cells 
suggests that this is a promising avenue of exploration as a viable strategy to 
increase control or eliminate viral infections through T cell modulation. Given the 
potential to restore anti-HIV-specific CD8 T cell responses by synergistic 
modulation of negative checkpoint receptors, we investigated the expression and 
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function of TIGIT in HIV disease pathogenesis, and in the SIV non-human 
primate model of HIV/AIDS.  
 
RESULTS 
 
Expansion of TIGIT+ T cells during HIV infection and correlations with 
clinical parameters of HIV disease progression, T cell activation, and the 
CD4 cell-associated HIV DNA content. 
 We assessed the surface expression of TIGIT on T cells from peripheral 
blood mononuclear cells (PBMCs) from HIV-infected individuals that were either 
acutely infected (AI), non-controllers (NC), cART suppressed (AS), or elite 
controllers (EC), and compared these results to age-matched HIV-uninfected 
donors (HD) (Table 3.1; Figure 1A-D; Supplemental Figure 3.1A,B). We 
observed a significant expansion in the frequency of TIGIT+ CD8 T cells in HIV-
infected participants (AS; 44.95%; EC 56.7%; NC, 64.5%), even among those 
with viral suppression, relative to HD (median: 28.05%; Figure 3.1C). We 
observed a non-significant trend in the expansion of TIGIT+ CD8 T cells in AI 
(40.4%) relative to HD (Figure 3.1C). TIGIT+ CD4 T cells were significantly 
elevated among NC (24.5%) compared to HD (16.05%) (Figure 3.1D).  
 Among the HIV-infected NC, TIGIT+ CD8 T cells inversely correlated with 
CD4 T cell counts, but not with CD8 T cell activation or plasma viral load (Figure 
3.1E; Supplemental Figure S1E). TIGIT+ CD4 T cells did not correlate with CD4 
cell counts in NC (Figure 3.1F). Among the EC, TIGIT+ CD8 T cells trended to 
correlate with CD8 T cell activation, while frequencies of TIGIT+ CD4 T cells 
correlated with CD4 T cell activation (Figure 3.1G,H). We did not observe any 
other significant correlations with TIGIT+ T cells (Supplemental Figure 3.1C-
F,G,I). Given the high levels of TIGIT in the midst of viral suppression, we 
assessed the relationship between TIGIT and the cellular HIV content in highly 
purified CD4 T cells among HIV-infected “cART initiators” who met strict selection 
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criteria of well documented and long-term persistent viral suppression (L-AS; 
Table 3.1). We did not observe a correlation with the frequency of CD8 T cell or 
CD4 T cell TIGIT expression and HIV RNA from purified CD4 T cells 
(Supplemental Figure 3.1H,J). However, the frequency of TIGIT+ CD4 T cells 
positively correlated with purified CD4 T cell HIV DNA content, but not with 
frequency of TIGIT+ CD8 T cells (Figure 3.1I,J). These data indicate that TIGIT 
expression on CD4 T cells may be linked to chronic HIV disease pathogenesis, 
residual immune activation, and the cellular HIV DNA content among those with 
viral suppression. 
 
Phenotype and function of TIGIT on CD8 T cells during HIV infection. 
HIV infection leads to an expansion of intermediately differentiated 
memory CD8 T cells that are not fully mature effectors [231-233]. We profiled the 
pattern of TIGIT expression in the heterogeneous CD8 T cell subpopulations and 
found TIGIT was significantly expanded on the CD8 T cell 
intermediate/transitional and effector subsets with the highest expression of 
TIGIT on the effector CD8 T cell subset (Figure 3.2A; Supplemental Figure 2A-E) 
compared to AS. In the naïve population TIGIT expression was relatively stable 
with only a significant difference seen between HD and the non-controllers 
(Figure 3.2A). We did observe a statistically significant difference in TIGIT 
expression between the HD and AI group in the memory CD8 T cell population 
(Figure 3.2A). Thus, TIGIT is expanded on the intermediate/transitional and 
effector CD8 T cell subsets during chronic HIV infection, consistent with a role for 
TIGIT as potential regulator of intermediate/transitional and effector T cell 
responses. 
 We next profiled the expression of TIGIT on viral-specific CD8 T cells from 
chronically HIV-infected participants using matched HLA-I restricted pentamers 
for various HIV and CMV peptide epitopes. TIGIT was expressed on over half of 
all CD8 T cells for specific for HIV Gag (55.3%), Polymerase (54.7%), Envelope 
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(54.3%), Nef (52%), and also for CMV pp65 (57.8%) (Figure 3.2B,C). 
Comparable levels of TIGIT on HIV and CMV specific CD8 T cells were observed 
on a per cell basis as measured by Geometric Mean Fluorescence Intensity 
(GMFI) (Figure 3.2C).  
We next assessed the effector phenotype and functional properties of 
TIGIT expressing CD8 T cells to determine whether they retain features of 
immune exhaustion. We found that most of the TIGIT expressing CD8 T cells co-
expressed PD-1 with the frequency of TIGIT+ PD-1+ CD8 T cells significantly 
expanded in chronic HIV infection (AS, 18.65%; EC, 20.85%; NC, 38.15%) 
compared to HD (13.65%) (Figure 3.3A,B). The frequency of TIGIT+ PD-1+ CD8 
T cells inversely correlated with CD4 T cell counts (Fig 3.3C) and positively 
correlated with plasma viral load levels (Figure 3.3D) among all chronically HIV-
infected individuals. We observed significantly higher frequencies of TIGIT+PD-
1+ co-expression on HIV-Gag-specific CD8 T cells compared to non-HIV-Gag-
specific CD8 T cells derived from PBMCs (Figure 3.3E-G). Furthermore, the 
majority of the TIGIT+PD-1+ HIV-Gag-specific CD8 T cells retained a 
transitional/intermediate memory (CD45RA-CCR7-CD27+) phenotype (Figure 
3.3H-J). These results suggest TIGIT may render a large fraction of viral specific 
CD8 T cells vulnerable to negative regulation. 
Given the high expression of PD-1 among TIGIT+ CD8 T cells, we 
evaluated the functional status of the TIGIT expressing cells. We stained T cells 
with the nuclear antigen Ki-67, which is associated with cellular proliferation, and 
observed that TIGIT+ cells expressed significantly more Ki-67 than TIGIT- CD8 T 
cells (Figure 3.4A,B). However, in contrast, Ki-67 expression was equivalently 
distributed between PD-1+ and PD-1- CD8 T cells (Figure 3.4C,D). Using 
intracellular cytokine staining, in response to stimulation with an overlapping 
15mer HIV Gag peptide pool, we observed that TIGIT+ CD8 T cells produced 
significantly less IFN-γ, TNF-α and IL-2 compared to TIGIT- CD8 T cells (Figure 
3.4E,F). We observed phenotypically the majority of the HIV specific cytokine 
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responsive CD8 T cells lacked TIGIT and PD-1 dual expression and were 
minimally represented in the TIGIT+PD-1+ subset. However, single expressing 
cells retain some functional responses (Figure 3.4G).  
To directly assess the functionality of the TIGIT+PD-1+ subset in HIV 
infected individuals, CD8 T cells expressing TIGIT and/or PD-1 on their surface 
were sorted to high purities (Supplemental Figure 3.3A,B), stimulated with or 
without anti-CD3 + anti-CD28 Dynabeads, and assessed for changes in TIGIT 
and PD-1 expression and their capacity to secrete 13 different cytokines. We 
found CD8 T cells lacking TIGIT (TIGIT-PD-1- and TIGIT-PD-1+) robustly 
upregulated TIGIT upon stimulation (Supplemental Figure 3.3B,C). Irrespective 
of PD-1 expression, the TIGIT expressing (TIGIT+PD-1- and TIGIT+PD-1+) cells 
only marginally increased TIGIT expression (Supplemental Figure 3.3B,C) upon 
stimulation. We harvested the supernatants and observed that TIGIT+PD-1+ 
cells had the lowest secretion of all cytokines assessed in comparison to the 
other three subsets (Supplemental Figure 3.3D). TIGIT+PD-1- cells produced 
less cytokines than TIGIT-PD-1+ cells. These data are partially in alignment with 
results observed in Figure 4G. However, it was notable that IL-10 production was 
almost exclusively produced by the TIGIT-PD-1+ cell subset. These data 
suggests that TIGIT+ CD8 T cells, particularly TIGIT+PD-1+ co-expressing CD8 
T cells exhibit distinguishing features of exhausted T cells. 
 Next, we evaluated the intracellular granular content of TIGIT expressing 
cells. We observed that TIGIT expressing CD8 T cells contained significantly 
more perforin and granzyme B compared to non-TIGIT expressing CD8 T cells 
(Figure 3.4H,I). We observed no difference in the ability of TIGIT+ CD8 T cells to 
degranulate compared to TIGIT- CD8 T cells when stimulated with HIV Gag 
peptide pool (Figure 3.4J,K). However, upon stimulation with anti-CD3 + anti-
CD28 Dynabeads, TIGIT+ cells degranulated less than TIGIT- cells (Figure 3.4J-
L).  
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Induction of TIGIT on CD8 T cells during HIV infection. 
 To explore the regulation of TIGIT expression we stimulated HIV-specific 
CD8 T cells from chronically HIV-infected individuals with HIV Gag peptides. HIV 
Gag peptide stimulation did not significantly increase the expression of TIGIT on 
HIV-specific CD8 T cells, although we did observe an upregulation of TIGIT in a 
subset of individuals (Figure 3.5A-C). Several common gamma-chain (γ-chain) 
cytokines have been shown to directly upregulate negative checkpoint receptors 
on CD8 T cells during retroviral infections [234]. To further understand the 
mechanism driving TIGIT upregulation, we explored the capacity of γ-chain and 
non-γ-chain cytokines to regulate TIGIT expression (Figure 3.5D-F). We found 
that IL-2 and IL-15 prominently led to a significant increase in TIGIT expression 
on CD8 T cells from HIV-infected individuals unlike non-γ-chain cytokines IL-12 
and IL-18 (Figure 3.5E). This effect was not evident on CD8 T cells derived from 
HIV-uninfected participants (Figure 3.5F). Correspondingly, TIGIT expression on 
CD4 T cells was upregulated primarily by IL-2 and IL-15 in HIV-infected 
individuals (Supplemental Figure 3.4A). IL-21 stimulation increased TIGIT 
expression on CD8 T cells, but not CD4 T cells (Supplemental Figure 3.4B). 
These data suggests that TIGIT expression may be regulated by a peripheral 
cytokine milieu dominated by γ-chain cytokines present during HIV infection. 
 
Effects of anti-TIGIT and anti-PD-L1 mAb blockade on HIV-specific CD8 T 
cell cytokine and proliferative responses. 
 Since TIGIT and PD-1 are co-expressed, and dual blockade in the mouse 
model limits in vivo LCMV replication [217] and elicits anti-tumor CD8 T cell 
responses [230], we evaluated the effects of TIGIT and PD-L1 blockade on HIV-
Gag-specific CD8 T cells using cells from chronically HIV-infected individuals at 
various stages of infection (Table 3.2). To evaluate the ex vivo HIV-specific T cell 
cytokine restoration, we used a modified version of our previously published in 
vitro short-term primary recall blockade assay [178]. Incubation with either anti-
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TIGIT mAb alone or anti-PD-L1 mAb alone significantly increased IFN-γ 
production, however dual blockade of both TIGIT and PD-L1 did not enhance 
IFN-γ responses over anti-TIGIT or anti-PD-L1 alone (Figure 3.6A,B). We also 
observed that only dual blockade of TIGIT and PD-L1 significantly increased IL-2 
production by CD8 T cells (Supplemental Figure 3.5A,B). Given that virus-
specific IL-2 producing CD4 T cells have been associated with disease control in 
HIV infection we assessed the effects of TIGIT blockade on CD4 T cells [235, 
236]. Similarly, only dual blockade of TIGIT and PD-L1 significantly increased IL-
2 production over the single blockades alone from CD4 T cells (Supplemental 
Figure 3.5C,D). 
Single blockade of PD-L1 significantly enhanced HIV-specific CD8 T cell 
proliferation while single blockade of TIGIT did not improve CD8 T cell 
proliferation (Figure 3.6C,D). When both anti-TIGIT and anti-PD-L1 were 
combined there was significant increased CD8 T cell proliferation compared to 
PD-L1 blockade alone (Figure 3.6C,D). Though donor OM115 had the highest 
baseline levels of TIGIT+ CD8 T cells among the group, no significant 
association was seen between the magnitude of IFN-γ production and 
proliferation by TIGIT blockade and baseline TIGIT+ CD8 T cell expression (r = 
0.24, p = 0.257). These data suggests that HIV-specific CD8 T cell proliferation 
can be markedly improved with simultaneous combination blockade of TIGIT and 
PD-L1. 
 
rhTIGIT is elevated on dysfunctional effector CD8 T cells in the SIV rhesus 
macaque model of HIV/AIDS and is associated with SIV disease 
progression. 
 To explore the role of TIGIT in the rhesus macaque model of HIV/AIDS we 
cloned rhesus TIGIT (rhTIGIT) (GenBank: KR534505) and observed that it 
shares 88.11% sequence homology with human TIGIT (Supplemental Figure 
3.6A). We reasoned that rhTIGIT expression and function would mimic our 
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human HIV studies and be replicable in the SIV-infected rhesus macaque model 
of HIV/AIDS. RhTIGIT expression was significantly increased on CD8 T cells 
derived from the lymph node (LN) (38.6%) and splenic (60.9%) compartments 
when compared to SIV-uninfected macaques (LN 10.82% and spleen 25.55%), 
but not in PBMCs (Figure 3.7A; Supplemental 3.6B). Similar to what we observed 
in HIV-infected participants, the frequency of rhTIGIT+ CD8 T cells from PBMC 
did not correlate with plasma SIV viral load. However, we did observe a 
significant correlation with the frequencies of rhTIGIT+ CD8 T cells in LN and 
viral load (Figure 3.7B). 
As observed in human HIV infection, rhTIGIT expression was more 
prominently expressed in SIV infection on effector memory (EM, CD28-CD95+), 
and central memory (CM, CD28+CD95+) CD8 T cells when compared to naïve 
(N, CD28+CD95-) CD8 T cells from PBMCs, LN and from the spleen 
(Supplemental Figure 3.6C). In the tissues, it was notable that TIGIT expression 
was highest on the central memory CD8 T cells when compared to PBMCs 
(Supplemental Figure 6C). As in HIV infection, stimulation with γ-chain cytokines 
such as IL-2 and IL-15 upregulated rhTIGIT on CD8 T cells from SIV-infected 
animals (Supplemental Figure 3.6D). 
 rhTIGIT was also expressed on ~40% of SIV Gag or Tat tetramer specific 
CD8 T cells derived from PBMCs or secondary lymphoid tissues, even in animals 
with full cART suppression of peripheral SIV viremia (Figure 3.7C). This was 
more prominently found in the tissues of SIV-infected animals where higher 
frequency of SIV-specific CD8 T cells co-expressed both rhTIGIT and rhesus 
macaque PD-1 (rhPD-1) (Supplemental Figure 3.6E-H).  
 While the levels of Ki-67 expression did not differ between rhTIGIT+ and 
rhTIGIT- CD8 T cells from SIV-infected rhesus macaques (Supplemental Figure 
3.7A-D), CD8 T cells lacking rhTIGIT from PBMC produced significantly more 
IFN-γ compared to rhTIGIT+ CD8 T cells when stimulated with either phorbol 12-
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mysistate 13-acetate (PMA) + ionomycin or SIV Gag181-189 CM9 peptide 
(Figure 3.7D,E). 
 Given the similarities of rhTIGIT and human TIGIT, we evaluated TIGIT 
and PD-L1 blockade on SIV peptide stimulated CD8 T cell responses. We found 
that dual blockade of rhPD-L1 and rhTIGIT enhanced SIV-specific CD8 T cell 
proliferation in PBMCs and spleen while single blockade of rhPD-L1 enhanced 
SIV-specific proliferation in the spleen (Figure 3.7F,G). Taken together, rhTIGIT 
pathway is active in the rhesus macaque model of HIV/AIDS and partially mimics 
human TIGIT expression and function during HIV infection. 
 
DISCUSSION 
 
In this report we profiled TIGIT expression on T cells in HIV-infected 
participants with various degrees of viral control and in SIV-infected rhesus 
macaques. We (1) unveil a role for TIGIT+ CD8 T cells in HIV disease 
progression and demonstrate its relation to T cell exhaustion, (2) observe that 
TIGIT appears to associate with the cellular viral reservoir in CD4 T cells, (3) we 
found that co-blockade of TIGIT and PD-L1 lead to a greater restoration of T cell 
function compared with a single blockade, and (4) by successfully cloning 
rhTIGIT (GenBank: KR534505) we reveal the similarities in expression and 
function of rhTIGIT on T cells in the non-human primate model of HIV/AIDS. Our 
findings reveal a novel inhibitory pathway involved in the suppression of T cell 
responses during chronic viral infection, the blockade of which may contribute to 
the reversal of T cell dysfunction in the control or elimination of HIV infection. 
While TIGIT levels on CD8 T cells tracked disease progression (depletion 
of CD4 T cells and T cell activation), this was not evident across the various HIV-
infected groups. There was a significant difference in TIGIT+ memory CD8 T 
cells in acute infection compared to the uninfected group, but not in the global 
CD8 T cell population. This suggests there may be a gradient, with an increase in 
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global TIGIT+ CD8 T cells in acute infection that becomes greater over time, 
which is distributed among the differentiated CD8 T cell populations and may 
differ when compared to other negative checkpoint receptors which are found 
elevated during the early stages of HIV infection [177, 237, 238].  
TIGIT induction appears to be driven by polyclonal TCR stimulation and 
this is a common feature among immune checkpoint receptors [237, 239]. We 
observed HIV-Gag-SL9-specific CD8 T cells did not increase TIGIT expression 
after HIV Gag peptide stimulation as a group, however a subset of individuals 
with moderate levels of TIGIT increased expression after stimulation, and 
individuals that expressed high levels of TIGIT retained expression after 
stimulation. TIGIT remained elevated despite antigen in cART-suppressed 
individuals, previous studies have also shown that common γ-chain cytokines 
maintain the ability to regulate immune checkpoint receptor expression in the 
absence of antigenic stimulation [234, 240]. Our studies align with these previous 
observations and suggest that a cytokine milieu conducive for the maintenance 
of an exhausted T cell profile persists in HIV and SIV infection even during viral 
suppression. 
TIGIT expression was found to be associated with T cell activation 
principally among ECs who represent a small population of HIV-infected 
individuals able to spontaneously suppress their viral load (<50 copies/ml) in the 
absence of cART for prolonged periods of time [241]. However, over time a 
subset of EC loses virologic control and develops viremia and CD4 T cell loss 
[242, 243]. In addition, EC maintain elevated levels of T cell activation despite 
viral control [92, 244]. High TIGIT expression may reflect ongoing immune 
activation in the EC population. The institution of cART in those EC has lead to a 
reduction in immune activation [245, 246]. Given our finding, in addition to cART, 
some EC may benefit from TIGIT blockade to alleviate the persistent T cell 
immune activation thereby reducing the risk of adverse non-AIDS events that 
have been documented to occur in this population, however such strategies need 
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to be considered carefully given the risk of autoimmunity as described in anti-PD-
1 clinical trials in the oncology field [247, 248].  
Viral clearance of the chronic strain of LCMV (clone 13) in mice by 
combined blockade of TIGIT and PD-L1 provided the first evidence of the 
advantages of targeting these two pathways [217]. In addition, targeting TIGIT 
and PD-L1 on CD8 tumor infiltrating lymphocytes in patients with advanced 
melanoma synergistically improves potent anti-tumor responses [230]. Here we 
extend these finding to human and simian retroviral infections. This was 
significant given the expansion of dual expressing TIGIT and PD-1 CD8 T cells in 
HIV infection despite pharmacological or immunological viral suppression. Our 
data shows the presence of TIGIT and PD-1 dual expressing HIV and SIV-
specific CD8 T cells and co-blockade of TIGIT and PD-L1 better enhanced 
proliferation of HIV and SIV-specific CD8 T cell responses compared to single 
blockade. Although we see a significant increase among all HIV-infected 
individuals, it was evident that subsets of weak-responders exist and appear 
heterogeneous irrespective of stage of infection, viral load levels or viral 
suppression. Indeed, combinational blockade of CTLA-4 and PD-1 revealed a 
subset of weak-responders to anti-tumor activity. Different or expanded 
combinations of immune checkpoint blockers with anti-TIGIT may need to be 
considered in the arsenal to improve anti-viral T cell immunity in all individuals.  
 Persistence of the cellular latent HIV reservoir has been a major barrier to 
the eradication of HIV [249]. One proposed strategy is to “Shock” the latently 
infected cells to flush out virus with latency reversal agents (LRAs) [206, 250, 
251]. The development of the “Shock” strategies is advancing at a rapid pace 
with in vivo studies yielding activity in reactivating of latent virus. However, the 
“Kill” component is less well developed. Shan and colleagues demonstrate that 
after reactivation of latent virus from CD4 T cells, CD8 T cells’ activity had the 
capacity to kill latently infected CD4 T cells if appropriate pre-stimulation of HIV 
peptide and IL-2 was provided an in vitro latency assay using Bcl-2 as a survival 
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signal to prolong the longevity of the latent CD4 T cells [252]. Furthermore, 
recent studies show that HIV-infected individuals on cART retain broad HIV-
specific cytotoxic T-lymphocyte responses that are able to target the mutated 
latent virus [253]. Blocking immune checkpoint pathways such as TIGIT and PD-
1/PD-L1 can be harnessed to boost HIV-specific CD8 T cells responses given 
that these pathways persist in the setting of viral suppression. Furthermore, given 
our findings showing the relationship with TIGIT expression on CD4 T cells and 
the total cell associated HIV DNA, it remains unclear what role TIGIT may play in 
the establishment of the reservoir in CD4 T cells, however it is likely related to 
the capacity of TIGIT’s ability control T cell activation or proliferation.  
Our study provides a novel role for TIGIT during HIV disease 
pathogenesis and our demonstration of a role of rhTIGIT in the non-human 
primate model of HIV/AIDS provides a platform to investigate our understanding 
of the complex networks of co-inhibition that can be tailored to each individual or 
viral infection. Improving CD8 T cell functions may further aid in the “Shock and 
kill” approaches being considered to eliminate latent virus and improve T cell 
mediated vaccine responses to prevent or limit infection [1]. 
 
MATERIALS AND METHODS 
 
Study participants 
 We recruited participants from the following cohorts: University of 
California, San Francisco (UCSF) SCOPE and OPTIONS cohorts [178] the 
Hawaii HIV (HHC) cohort, the Toronto-based cohort CIRC (Maple Leaf Clinic and 
St. Michael’s Hospital, Toronto, Canada) [254] and the Duke Human Vaccine 
Institute (DHVI) tissue repository. SCOPE specimens (n = 80) were selected from 
the following groups: untreated non-controllers (n = 20) (participants who had 
never been treated with antiretroviral agents or who had been off therapy for at 
least six months), treated virologic controllers (participants who had an 
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undetectable plasma HIV RNA level for the previous six months while on cART) 
(n = 20), spontaneous “elite” virologic controllers (participants who are untreated 
and who have at least three documented plasma HIV RNA levels <2,000 
copies/ml over at least a 12-month period) (n = 20), Some of these participants 
had persistent plasma HIV RNA levels <75 copies/ml) and HIV-infected “cART 
initiators” (n = 20) who meet strict selection criteria and well documented 
persistent viral suppression for over 1.5 years. Participants with acute HIV 
infection (n = 24) were obtained for the OPTIONS cohort of primary HIV infection 
[178] and age-matched HIV-uninfected (n = 20) (Table 1) and chronically infected 
virally suppressed leukapheresesed individuals were obtained from the HAHC 
cohort [255]. Additional participants with chronic infection at various stages of 
infection were obtained from participants with various levels of viral control from 
the Toronto-based cohort CIRC cohort, HHC, and DHVI.  
 
Ethics Statement 
 All persons gave written informed consent to participate in the study and 
approval for the study was obtained from the University of Hawaii Committee of 
Human Subjects. Samples were obtained from Indian Rhesus macaques 
(Macaca mulatta) housed at the Oregon National Primate Research Center 
(ONPRC), which were SIV infected for other ongoing, unrelated studies. Oregon 
Health & Science University (OHSU) Institutional Animal Care and Use 
Committee (IACUC) Protocol #: 0989. The OHSU Institutional Animal Care and 
Use Committee reviewed and approved all study protocols. All macaques in this 
study were managed according to the ONPRC animal husbandry program, which 
aims at providing consistent and excellent care to nonhuman primates. This 
program is based on the laws, regulations, and guidelines set forth by the United 
States Department of Agriculture (e.g., the Animal Welfare Act and its 
regulations, and the Animal Care Policy Manual), Institute for Laboratory Animal 
Research (e.g., Guide for the Care and Use of Laboratory Animals, 8th edition), 
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Public Health Service, National Research Council, Centers for Disease Control, 
and the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) International. The nutritional plan utilized by the ONPRC is based on 
National Research Council recommendations and supplemented with a variety of 
fruits, vegetables, and other edible objects as part of the environmental 
enrichment program established by the Behavioral Management Unit. 
Paired/grouped animals exhibiting incompatible behaviors were reported to the 
Behavioral Management staff and managed accordingly. All efforts were made to 
minimize suffering through the use of minimally invasive procedures, anesthetics, 
and analgesics when appropriate. Animals were painlessly euthanized with 
sodium pentobarbital and euthanasia was assured by exsanguination and 
bilateral pneumothorax, consistent with the recommendations of the American 
Veterinary Medical Guidelines on Euthanasia (2013). 
 
Quantifying cellular HIV DNA and RNA 
 Cryopreserved PBMCs were rapidly thawed and enriched for CD4 T cells 
to high purities with an EasySep Human CD4 T cell enrichment kit (Stemcell 
Technologies, Vancouver, British Columbia, Canada). Cellular RNA and DNA 
from PBMC T-cell subsets cells were purified using the AllPrep DNA/RNA kit 
(Qiagen, Ventura CA) as specified by the manufacturer, quantified using a 
Nanodrop (ND-1000) spectrophotometer and normalized to cell equivalents by 
qPCR using human genomic TERT for DNA and GAPDH or RPLP0 expression 
for RNA (Life Technologies, Grand Island NY). Total cellular HIV DNA (integrated 
and unintegrated) and RNA (unspliced and multiply spliced) was quantified with a 
qPCR TaqMan assay using LTR-specific primers F522-43 (5’ GCC TCA ATA 
AAG CTT GCC TTG A 3’; HXB2 522-543) and R626-43 (5’ GGG CGC CAC TGC 
TAG AGA 3’; 626-643) coupled with a FAM-BQ probe (5’ CCA GAG TCA CAC 
AAC AGA CGG GCA CA 3) [256] on a StepOne Plus Real-time PCR System 
(Applied Biosystems Inc, Foster City CA). Cell associated HIV DNA copy number 
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was determined using a reaction volume of 20 µl with 10 µl of 2x TaqMan 
Universal Master Mix II including UNG (Life technologies), 4 pmol of each primer, 
4 pmol of probe, and 5 µl of DNA. Cycling conditions were 50 °C for 2 min, 95 °C 
for 10 min, then 60 cycles of 95 °C for 15s and 59 °C for 1 min. Cell associated 
HIV RNA copy number was determined in a reaction volume of 20 µl with 10 µl of 
2x TaqMan RNA to Ct 1 Step kit (Life Technologies), 4 pmol of each primer, 4 
pmol of probe, 0.5 µl reverse transcriptase, and 5 µl of RNA under identical 
cycling conditions. For HIV DNA measurements, external quantitation standards 
were prepared from pNL4-3 in a background of HIV negative human cellular 
DNA, calibrated to the Virology Quality Assurance (VQA, NIH Division of AIDS) 
cellular DNA quantitation standards. For HIV RNA measurements, external 
quantitation standards were prepared from full length NL4-3 virion RNA followed 
by copy number determination using the Abbott RealTime assay (Abbott 
Diagnostics, Des Plains Ill) and calibrated to VQA HIV RNA standards. Patient 
specimens were assayed with up to 800 ng total cellular RNA or DNA in replicate 
reaction wells and copy number determined by extrapolation against a 7-point 
standard curve (1 – 10,000 cps) performed in triplicate. 
 
Antibodies and flow cytometric analysis. 
 Cryopreserved PBMC were rapidly thawed in warm 10% cRPMI ((RPMI 
1640 medium; (Hyclone, Logan, Utah) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone), 1% penicillin-streptomycin (Hyclone), 10 mM HEPES 
(Hyclone), 2 mM L-glutamine (Hyclone), and 10 µg/ml DNase I (Sigma-Aldrich, 
Dorset, United Kingdom)), washed with PBS + 2% FBS (Hyclone) (complete 
RPMI). Cells were stained for viability with an aqua amine reactive dye (AARD; 
Invitrogen, Carlsbad, California), then incubated with panels of conjugated anti-
human monoclonal antibodies (mAbs) The following directly conjugated mAbs 
used in this study were obtained from BD biosciences (San Jose, California): PE-
Cy5-conjugated anti-CD38 (Clone: HIT2), V450-conjugated anti-CD45RA 
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(HI100), FITC-conjugated anti-CD45RA (HI100), PerCP-Cy5.5-conjugated anti-
CD27 (M-T271), Alexa Flour 700-conjugated anti-CD4 (RPA-T4), FITC-
conjugated anti-HLA-DR (G46-6), APCH-7-conjugated anti-CD8 (SK1), FITC-
conjugated anti-CD57 (NK-1), APC-conjugated CD107a (H4A3). mAb obtained 
from Beckman Coulter (Fullerton, California) ECD-conjugated anti-CD3 (UCHT1). 
mAbs obtained from eBioscience (San Diego, California) PE-Cy7-conjugated 
anti-CD28 (CD28.2), PerCP-eFluor 710-conjugated anti-TIGIT (MBSA43), PE-
conjugated anti-TIGIT (MBSA43), Mouse IgG1 Kappa isotype control PerCP-
eFluor 710 (P3.6.2.8.1), mouse IgG1 K isotype control PE (P3.6.2.8.1). mAbs 
obtained from Biolegend (San Diego, California) Brilliant Violet 605-conjugated 
anti-CCR7 (G043H7), APC-conjugated anti-PD-1 (EH12.2H7), mouse IgG1 
Kappa isotype control PE (MOPC-21). Qdot 605-conjugated anti-CD8 (3B5) was 
obtained from Invitrogen (Carlsbad, California). In some experiments cells were 
fixed with 1X Lyse buffer (BD Biosciences) followed by 1X BD FACS 
Permeabilizing solution 2 (BD Biosciences) and stained with FITC-conjugated Ki-
67 (35/Ki-67), FITC-conjugated interferon gamma (IFN-γ) (25723.11), Alexa 700-
conjugated Granzyme B (GB11), PE-conjugated perforin (B-D48) (abcam, 
Cambridge, Massachusetts). All cells were washed with PBS + 2% FBS and then 
fixed in 1% paraformaldehyde (PFA, Electron Microscopy Sciences, Hatfield, 
Pennsylvania) before acquiring (within 18 hours) on a custom four laser 
LSRFortessa flow cytometer (BD Biosciences). Between 100,000 to 500,000 
lymphocyte events were collected for each sample. Isotype controls or 
fluorescence minus one (FMO) samples were prepared to facilitate gating. Anti-
mouse or anti-rat IgG-coated beads (BD Biosciences) were individually stained 
with each fluorochrome-conjugated antibody and used for software-based 
compensation. Data were analyzed using Flowjo Software version 9.5 (Treestar, 
Ashland, Oregon).  
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Cell Sorting 
 Cryopreserved PBMCs were rapidly thawed and enriched for CD8 T cells 
to high purities with an EasySep Human CD8 T cell negative selection 
enrichment kit (Stemcell). Cells were surface stained with the following 
combination of mAbs: BV711-conjugated anti-CD3, Alexa 700-conjugated anti-
CD4 (BD Biosciences), PerCP-eFluor 710-conjugated anti-TIGIT (eBioscience), 
Qdot605-conjugated anti-CD8, APC-conjugated anti-PD-1 (Invitrogen). Cells 
were sorted on a BD FACS ARIA and checked for purity. Gating was facilitated 
by isotype controls. 
 
Multiplex cytokine assay 
 The four-sorted populations (TIGT+PD-1+, TIGIT+PD-1-, TIGIT-PD-1+, 
TIGIT-PD-1-) were seeded at 100,000 cells per well in a 96 well culture plate with 
200 µl of 10% cRPMI. Sorted cells were stimulated with anti-CD3 + anti-CD28 
Dynabeads (Life Technologies) for 48 hours in an incubator at 37 °C with 5% 
CO2, supernatants were harvested from the cultures and processed according to 
recommended manufacture procedure with a Milliplex MAP Human High 
Sensitivity T cell Panel (EMD Millipore, Billerica, Massachusetts) for GM-CSF, 
TNF-α, IL-13, IL-12 (p70), IL-10, IL-8, IL-7, IL-6, IL-5, IL-4, IL-2, IL-1b, IFN-
γ. Samples were acquired on a Luminex 200 (EMD Milipore). Samples were run 
in duplicate. The intra-assay CV% for the conditions of each cytokines were 
<10%. 
 
Peptides and polyclonal stimulation  
 123 Overlapping ~15mer HIV clade B gag peptides obtained from the 
National Institute of Health AIDS Reagent Program. Stimulations were performed 
with a final concentration of 10 µg/ml peptide. T cell activator (anti-CD3 + anti-
CD28 mAb Dynabeads) (Life Technologies) followed recommended manufacture 
procedure. 
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Pentamer analysis  
 We used the following Biotin labeled pentamers: A*02:01 SLYNTVATL 
HIV-Gag, A*02:01 ILKEPVHGV HIV-Pol, B*07:02 IPRRIRQGL HIV-Env, B*07:02 
TPGPGVRYPL HIV-Nef, and A*02:01 NLVPMVATV CMV-pp65-NV9. All 
pentamers were obtained from Proimmune Ltd, Oxford, UK. Using protocol 
outlined previously [178] and stained with antibodies against CD3, CD8, TIGIT, 
PD-1, TIGIT isotype control or PD-1 isotype control and acquired on the flow 
cytometer as above. In some experiments PBMCs were stimulated with HIV Gag 
Peptide pool and evaluated for pentamer phenotype. 
 
Anti-TIGIT and anti-PD-L1 monoclonal antibodies  
 The TIGIT antibody clones 11G11 and 23G8 were generated in HuMab 
mice [257, 258] immunized with a TIGIT-Fc fusion protein and selected based on 
their high affinity for TIGIT and ability to block TIGIT/PVR interaction. Clone 
11G11 is a fully human IgG1 antibody that was engineered to contain a well-
characterized set of mutation in the Fc that eliminate FcR interaction [259]. Clone 
23G8 is a fully human IgG2 antibody that cross-reacts with macaque TIGIT. The 
anti-human PD-L1 antibody, clone 12A4, is a fully human IgG4 (S228P) that was 
generated in HuMab mice immunized with PD-L1-Fc. This antibody was selected 
based on its ability to block the binding of PD-L1 to both PD-1 and CD80. 12A4 
cross-reacts with macaque PD-L1. 
 
Peptides and polyclonal stimulation 
 123 Overlapping ~15mer HIV clade B gag peptides obtained from the 
National Institute of Health AIDS Reagent Program. Stimulations were performed 
with a final concentration of 10 µg/ml peptide. T cell activator (anti-CD3 + anti-
CD28 mAb Dynabeads) (Life Technologies) followed recommended manufacture 
procedure. 
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Functional assays  
 In the intracellular cytokine stimulation assay studies, thawed 
cryopreserved PBMCs were stimulated for 12 hours in an incubator at 37 °C with 
5% CO2 with 5 µg/ml brefeldin A and 5 µg/ml monensin (Sigma-Aldrich) culture 
media, DMSO alone, pooled HIV Gag peptides, or anti-CD3/CD28 Dynabeads 
(Life Technologies) in the presence or absence of purified isotype IgG control, 
anti-TIGIT and/or anti-PD-L1 mAbs. After stimulation, the cells were washed and 
stained for viability with AARD and cultured with surface phenotype panel against 
CD8, TIGIT or an isotype control antibody, followed by intracellular staining of 
CD3 and IFN-γ and acquisition on the flow cytometer as above. For the 
proliferation assay, thawed PMBCs were washed two times and resuspended in 
PBS supplemented with 0.01% BSA at a concentration of one million cells per 
milliliter. Cells were labeled with 1mM Carboxyfluorescein succinimidyl ester 
(CFSE) violet-trace (Invitrogen) using protocols previously described [178]. Cells 
were stimulated for seven days with DMSO alone, pooled HIV gag peptides, or 
anti-CD3/CD28 Dynabeads in the presence or absence of purified isotype IgG 
control, anti-TIGIT or anti-PD-L1 at 37 °C with 5% CO2. At the end of the 
stimulation, cells were washed and stained for viability with AARD and cultured 
with surface phenotype panel against CD3, CD8, TIGIT or an isotype control 
antibody and acquired on the flow cytometer as above. 
 
In vitro cytokine stimulation 
 PBMCs were thawed and one million cells were plated per stimulation 
condition. Stimulation conditions included media alone, 25 ng/ml IL-2 (Roche), 50 
IU/ml of IL-12 (MBL international, Woburn, Massachusetts), 50 IU/ml of IL-18 
(MBL international) and 25 ng/ml IL-15 (R&D Systems, Minneapolis, Minnesota). 
Cells were stimulated for six days in an incubator at 37 °C with 5% CO2. After 
stimulation, the cells were washed and stained for viability with AARD cultured 
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with surface phenotype panel against CD3, CD4, CD8, TIGIT or isotype control 
antibody and acquired on the flow cytometer as above. 
 
T cell function in vitro antibody blockade studies. HIV-infected cryopreserved 
PBMC from individuals identified in Table 2 were stimulated for 12 hours in an 
incubator at 37 °C with 5% CO2. Stimulation conditions contained culture media, 
DMSO alone or pooled HIV gag peptides, in the presence of brefeldin A (Sigma-
Aldrich), monensin (Sigma-Aldrich), anti-TIGIT mAb anti-PD-L1 mAb or mouse 
IgG1 isotype control. After stimulation, cells were washed and stained for cellular 
viability with AARD and conjugated antibodies against CD8 and CD4, followed by 
intracellular staining of CD3 and IFN-γ and acquired on a flow cytometer as 
described above. 
 
Statistical analysis  
 The repeated-measures, one-way ANOVA followed by Tukey’s multiple 
comparison, Wilcoxon matched-pairs signed ranked test was used for paired 
tests and the Spearman’s rho test was used for correlation analyses. Measures 
of central tendency are expressed as medians and interquartile ranges (IQRs; 
given in the form 25th percentile, 75th percentile). Statistical analyses were 
conducted using Prism Graphpad release 5.0d (Graphpad Software, San Diego, 
California) or SPSS 22.0 (IBM, Armonk, New York) and the statistical 
significance of the findings was set at a p-value of less than 0.05.  
 
Accession Numbers  
 Indian rhesus macaque (Macaca mulatta) TIGIT (rhTIGIT): GenBank 
KR534505 
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TABLES 
 
TABLE 3.1: Participant Characteristics  
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TABLE 3.2: Description of participants for in vitro mAb blockade 
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Figure 3.1: Expression of TIGIT on T cells during HIV infection. 
Cryopreserved PBMCs were thawed and surface phenotyped for TIGIT 
expression. Representative flow cytometry flow plots showing TIGIT expression 
on (A) CD8 or (B) CD4 T cells compared to fluorescence minus one (FMO) 
control. Graphs show compiled data of TIGIT expression on (C) CD8 and (D) 
CD4 T cells stratified by disease: HIV-uninfected healthy donors (HD, X; n = 20), 
acute HIV-infection (AI, open diamond; n = 24), aviremic cART suppressed (AS, 
open triangles; n = 20), aviremic elite controllers (EC, open squares; n = 20), and 
chronic HIV viremic non-controllers (NC, open circles; n = 20). P values were 
calculated using one-way ANOVA, followed by Tukey’s multiple comparisons 
test. Graphs show correlation of total chronic infected (+: AS, EC, and NC; left 
panel, n = 60) and non-controllers (right panel, n = 20) frequency (%) of (E) 
TIGIT+ CD8+ and (F) TIGIT+ CD4 T cells against clinical CD4 Count 
(cells/mm3). Graphs show correlation of total chronic infected (+: AS, EC, and 
NC; left panel, n = 60) and elite controllers (right panel, n = 20) frequency (%) of 
(G) TIGIT+ CD8 and (H) TIGIT+ CD4 T cells against frequency (%) of T cell 
activation (CD38+HLA-DR+). Graphs show correlation of frequency (%) of (I) 
TIGIT+ CD8 and (J) TIGIT+ CD4 T cell among aviremic HIV infected “ART 
initiators” with known duration of long-term viral suppression from the SCOPE 
cohort (L-AS, n = 19, open inverted triangles) versus copies of CD4 T cell 
associated HIV DNA per million CD4 T cells (log10). Spearman’s rho tests were 
performed for correlations. 
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Figure 3.2: TIGIT expression on CD8 terminal effector T cells and HIV-
specific CD8 T cells. Cryopreserved PBMCs were thawed and surface 
phenotyped for TIGIT expression on CD8 T cell compartments. (A) Graph shows 
compiled frequency (%) of TIGIT+ CD8 T cell expression in differentiated 
compartments stratified by disease status. HIV-uninfected donors (HD, X; n = 
20), acute infected (AI, open diamond; n = 24), cART suppressed (AS, open 
triangle; n = 20), elite controller (EC, open square; n = 20), non-controllers (NC, 
open circle; n = 20). P values were calculated using one-way ANOVA, followed 
by Tukey’s multiple comparisons test (*p < 0.05; **p < 0.01; ***p < 0.001). 
PBMCs from HLA-A*02:01 or HLA-B*07:02 HIV chronically infected individuals 
were stained with matched HLA pentamers presenting HIV and CMV epitopes 
and anti-TIGIT. (B) Representative flow cytometry plots of pentamer-specific CD8 
T cells using HLA-A*02:01 HIV Gag SLYNTVATL (A2*SL9), HLA-A*02:01 HIV 
Pol ILKEPVHGV (A2*IV9), HLA-B*07:02 HIV-1 Env IPRRIRQGL (B7*IL9), HLA-
B*07:02 HIV Nef TPGPGVRYPL (B7*TL10), and HLA-A*02:01 CMV pp65 
NLVPMVATV (A2*NV9) (C) Compiled data of TIGIT expression frequency (%) on 
pentamer specific CD8 T cells which was recalculated to 100% (left panel, n = 9) 
compiled data of TIGIT geometric mean fluorescence intensity (GMFI) on 
pentamer specific CD8 T cells (right panel, n = 9). 
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Figure 3.3: HIV-Gag specific CD8 T cells co-express TIGIT and PD-1 and 
exhibit a transitional memory phenotype. Cryopreserved PBMCs were thawed 
and surface phenotyped for TIGIT and PD-1 expression on CD8 T cells. (A) 
Representative flow cytometry plots showing TIGIT and PD-1 expression on CD8 
T cells from one HIV-uninfected individual (left panel) and one HIV-infected 
individual (right panel). (B) Graph shows compiled frequency (%) of co-
expressing TIGIT+PD-1+ CD8 T cells from HIV-uninfected (HD, n = 20), chronic 
HIV-infected (AS, n = 20; EC, n = 20; NC, n = 20). P values were calculated 
using one-way ANOVA, followed by Tukey’s multiple comparisons test. (C) 
Graph shows correlation of TIGIT+PD-1+ CD8 T cells frequency (%) from chronic 
HIV-infected individuals against CD4 count (cells/mm3) or (D) viral load 
(copies/ml). Spearman’s rho tests were performed for correlations. TIGIT and 
PD-1 expression on HIV-Gag-specific CD8 T cells were evaluated. (E) 
Representative flow cytometry plot of HIV-specific CD8+ T cells using HLA-
A*02:01 HIV Gag SLYNTVATL. (F) Representative flow cytometry plots of TIGIT 
and PD-1 expression on HIV-Gag-specific CD8 T cells (Penta+, left panel; Penta-
, right panel). (G) Graphs show compiled frequency (%) of TIGIT and PD-1 on 
Penta+ (left panel) and Penta- (right panel) (sample group contains; AS n = 11, 
EC n = 2, NC n = 2). P values were calculated using repeated-measures one-
way ANOVA, followed by Tukey’s multiple comparisons test (*p < 0.05; **p < 
0.01; ***p < 0.001). Representative flow cytometry of (H) CD45RA and CCR7 or 
(I) histogram of CD27 (shaded isotype control) on Penta+ CD8 T cells expressing 
TIGIT+PD1+, TIGIT+PD-1-, TIGIT-PD-1+, or TIGIT-PD-1-. (J) Graphs show 
compiled frequency (%) of CD45RA (top panel), CCR7 (mid panel), and CD27 
(bottom panel) (n = 5). 
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Figure 3.4: TIGIT expressing CD8 T cells have impaired cytokine 
responses. Representative flow cytometry plots gated on CD8 T cells showing 
(A) TIGIT or (C) PD-1 expression against Ki-67 from a chronically HIV-infected 
individual. Compiled data of Ki-67+ CD8 T cell frequency (%) separated into (B) 
TIGIT+ and TIGIT- or (D) PD-1+ and PD-1- (n = 20). P values were calculated by 
Wilcoxon matched-pairs signed ranked test. Ex vivo PBMCs from chronically 
HIV-infected individuals were stimulated with HIV Gag peptide pool and 
assessed for cytokine production. (E) Representative flow cytometry plots gated 
on CD8 T cells showing TIGIT expression and either IFN-γ, IL-2, or TNF-α 
content after no stimulation, stimulation with an HIV Gag peptide pool, or a 
positive control stimulation with anti-CD3 + anti-CD28 Dynabeads. (F) Compiled 
data of IFN-γ, IL-2, or TNF-α CD8 T cell frequency (%) from TIGIT+ or TIGIT- 
CD8 T cell compartments after HIV Gag peptide pool stimulation (sample group 
includes; AS n = 4, EC n = 3, NC n = 3). P values were calculated by Wilcoxon 
matched-pairs signed ranked test. (G) Compiled data of TIGIT and PD-1 
expression on HIV Gag responding cells (sample group includes; AS n = 4, EC n 
= 3, NC n = 3). P values were calculated with repeated-measures one-way 
ANOVA, followed by Tukey’s multiple comparisons test (*p < 0.05; **p < 0.01; 
***p < 0.001). (H) Representative flow cytometry plots of intracellular perforin and 
granzyme B from CD8 T cells expressing or not expressing TIGIT. (I) Compiled 
frequency (%) of intracellular perforin+granzyme B+ content from TIGIT+ or 
TIGIT- CD8 T cell compartments (AS; n = 12). P values were calculated by 
Wilcoxon matched-pairs signed ranked test. (J) Representative flow cytometry 
plots gated on CD8 T cells showing TIGIT and CD107a expression from TIGIT 
isotype control, no stimulation, HIV Gag peptide pool, positive control stimulation 
with anti-CD3 + anti-CD28 Dynabeads. Compiled data of background corrected 
CD107a after (K) HIV Gag peptide pool (L) anti-CD3 + anti-CD28 Dynabead 
stimulation in TIGIT+ or TIGIT- CD8 T cell compartments (AS; n = 10). P values 
were calculated by Wilcoxon matched-pairs signed ranked test. 
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Figure 3.5: Common gamma chain cytokines regulate TIGIT expression on 
CD8 T cells.  
Ex vivo PBMCs from chronically HIV infected individuals were stimulated with 
HIV Gag peptide pool for 12 hours. (A) Representative flow cytometry plot gated 
on CD8 T cells showing HIV Gag pentamer with no stimulation (top panel) or HIV 
Gag stimulation (bottom panel). (B) Representative flow cytometry plot of TIGIT 
expression on Penta+ and Penta- cells with no stimulation or HIV Gag 
stimulation. (C) Graph shows compiled frequency (%) of TIGIT on Penta+ cells 
with no stimulation and HIV Gag stimulation (n = 9). P values calculated with 
Wilcoxon matched-pairs signed-rank test. (D) Representative flow cytometry 
histograms gated on CD8 T cells overlaid with TIGIT expression frequency 
before and after cytokine stimulation. Dashed line indicates TIGIT isotype control, 
shaded histogram indicates TIGIT expression with no stimulation, and the solid 
line indicates TIGIT expression with cytokine stimulation after six days. Compiled 
data of TIGIT frequency (%) on CD8 T cells (E) HIV-infected participant (open 
circle; n = 8) (F) HIV-uninfected participant (X; n = 5). P values were calculated 
with repeated-measures one-way ANOVA, followed by Tukey’s multiple 
comparisons test. 
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Figure 3.6: Effect of in vitro blockade with anti-TIGIT and anti-PD-L1 mAbs 
on HIV-specific CD8 T cell responses. Ex vivo PBMCs from chronically HIV-
infected individuals were stimulated with HIV Gag peptide pool in the presence of 
mAb blocking antibodies. (A) Representative flow cytometry plots gated on CD8 
T cells, showing IFN-γ responses from an HIV-infected individual. No HIV Gag 
stimulation with an isotype control, HIV Gag stimulation with an isotype control, 
HIV Gag stimulation with anti-TIGIT, HIV Gag stimulation with anti-PD-L1, HIV 
Gag stimulation with dual blockade (anti-TIGIT + anti-PD-L1) and a positive 
control (anti-CD3 + anti-CD28 Dynabeads). (B) Compiled data showing variation 
in the frequency (%) of IFN-γ in responses to HIV Gag peptide pool with isotype 
control or mAb blockade; TIGIT blockade (left panel), PD-L1 blockade (middle 
panel), and dual blockade (right panel) (n = 25). P values were calculated by 
Wilcoxon matched-pairs signed ranked test. (C) Representative flow cytometry 
plots gated on CD8 T cells from HIV-infected individuals, showing intermediate 
and high CFSE dilution in response to HIV Gag peptide pool stimulation in the 
presence of either an isotype control, anti-TIGIT mAb, anti-PD-L1 mAb, a 
combination of both anti-TIGIT and anti-PD-L1 mAbs or anti-CD3 + anti-CD28 
Dynabeads as a positive control. (D) Graphs show compiled data showing 
variation in the frequency (%) of CFSEdim in responses to HIV Gag peptide pool 
with either an isotype control or mAb blockade; TIGIT blockade (left panel), PD-
L1 blockade (middle panel), and dual blockade (right panel) (n = 24). P values 
were calculated by Wilcoxon matched-pairs signed ranked test. 
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Figure 3.7: Phenotypic and functional assessment of rhTIGIT CD8 T cells. 
Cryopreserved Rhesus macaque PBMCs were thawed, phenotyped and 
assessed for function. (A) Graphs show frequency (%) of rhTIGIT+CD8 T cells 
from PBMCs (circle), Lymph nodes (square; LNs), and Spleen (triangle) in SIV-
uninfected (filled) and SIV-infected (open) animals (SIV-uninfected PBMCs, n = 
8; SIV-infected PBMCs, n = 19; SIV-uninfected LNs, n = 8; SIV-infected LNs, n = 
22; SIV-uninfected spleen, n = 6; SIV infected spleen, n = 9). P values were 
calculated with Mann-Whitney U tests. (B) Graphs show correlation of frequency  
(%) of rhTIGIT+ CD8 T cells in PBMCs (circle) and lymph nodes (square) from 
SIV-infected animal against plasma SIV viral load log10 vRNA copy Eq/ml 
(PBMCs, n = 12; LNs, n = 20). vRNA copy Eq, viral RNA copy equivalents. 
Spearman’s rho tests were performed for correlations. (C) Representative flow 
cytometry plots of tetramer stains for Mamu-A*01 restricted SIV-Gag CM9 and 
SIV-Tat SL8 specific CD8 T cells from PBMC, LNs, and spleen, in a 
representative Mamu-A*01 animal with full cART suppression. Compiled data of 
rhTIGIT expression frequency (%) on tetramer specific CD8 T cells (n = 4) from 
PBMCs (circle), LNs (square), and spleen (triangle) from Mamu-A*01+ macaques 
with full cART suppression. (D) Representative flow cytometry plots of PBMCs (n 
= 12) or lymph nodes (n = 18) stimulated without or with PMA + Ionomycin. 
Graphs show frequency (%) of IFN-γ from CD8 T cells expressing TIGIT or not 
expressing TIGIT. P values were calculated by Wilcoxon matched-pairs signed 
ranked test. (E) Representative flow cytometry plots of PBMCs from a Mamu-
A*01+ macaque stimulated without or with SIV-Gag181-189 CM9 peptide. Graph 
shows frequency (%) of IFN-γ from SIV-Gag181-189 CM9-specific CD8+ T cells 
expressing TIGIT or not expressing TIGIT from Mamu-A*01+ macaques (n = 6). 
P values were calculated by Wilcoxon matched-pairs signed ranked test. (F) 
Representative flow cytometry plots of CD8 T cells from two separate SIV-
infected macaques showing CD8 T cell CFSE dilution in response to AT2-
inactivated SIV with either no antibody, anti-TIGIT, anti-PD-L1 or dual blockade 
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(anti-TIGIT + anti-PD-L1). (G) Graphs show compiled data of CD8 T cell CFSE 
dilution from PBMC (left panel), Lymph node (middle panel), or Spleen (right 
panel) as percent of max (n = 4). P values were calculated by Wilcoxon matched-
pairs signed ranked test. 
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SUPPLEMENTAL MATERIAL AND METHODS (NONHUMAN PRIMATES) 
 
Animals 
 Indian Rhesus macaques (Macaca mulatta), housed at the Oregon 
National Primate Research Center and used in this study, were cared for 
according to the laws, regulations, and guidelines set forth by the U.S. 
Department of Agriculture (e.g., the Animal Welfare Act and its regulations, and 
the Animal Care Policy Manual), Institute for Laboratory Animal Research (e.g., 
Guide for the Care and Use of Laboratory Animals, 8th edition), Public Health 
Service, National Research Council, Centers for Disease Control and Infection, 
and the Association for Assessment and Accreditation of Laboratory Animal Care 
International. The Oregon Health and Science University Institutional Animal 
Care and Use Committee approved the research involving animals reported in 
this study. Animals were infected with SIVsmE660, SIVmac239, or SIVmac251 
for other, unrelated projects. 
 
Antibodies and flow cytometric analysis 
 The following directly conjugated Abs were obtained from BD Biosciences: 
Alexa Fluor 700–conjugated anti-CD3 (SP34-2), PE-CF594–conjugated anti-CD4 
(L200), allophycocyanin- or allophycocyanin-H7–conjugated anti-CD8 (SK1), PE-
Cy5–conjugated anti-CD95 (DX2), allophycocyanin-conjugated anti–IFN-γ (B27), 
and PE-conjugated anti–Ki-67 (B56). PE-conjugated anti–PD-1 (EH12.2H7), and 
PE-Cy7–conjugated CD28 (CD28.2) were obtained from Biolegend. PE-
conjugated anti-TIGIT (MBSA43) was obtained from eBioscience. 
Allophycocyanin-conjugated Mamu-A*01 SIV Gag181–189 CM9 (CTPYDINQM) 
tetramer and allophycocyanin-conjugated Mamu-A*01 SIV Tat28–35 SL8 
(STPESANL) tetramer were produced as described previously [260]. An aqua 
amine reactive dye (Invitrogen) was used to exclude dead cells. In some 
experiments, cells were fixed in 2% paraformaldehyde (PFA), permeabilized with 
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BD FACS permeabilizing solution 2 (BD Biosciences), and stained for Ki-67 and 
IFN-γ (BD Biosciences).  
 
Cloning and sequencing of rhesus macaque TIGIT 
 Total RNA was purified from fresh rhesus PBMC using the AllPrep 
DNA/RNA kit (QIAGEN, Venlo, Limburg, The Netherlands). TIGIT was reverse 
transcribed with Superscript III One-Step RT-PCR System with Platinum Taq 
High Fidelity (Invitrogen) using primers 5’-ATGCGGTGGTGTCTCTTCC-3’ and 
5’-CTACCCAGTCTCTGTGAAGAAGC-3’. The amplicon was purified from a 1% 
agarose gel and sequenced using the same primers, in addition to internal 
sequencing primers, 5’-ACTCAGCATTACGAATGGCCAG-3’ and 5’-
ACTGGACAGGAAGAACAGATTCC-3’ to cover the 5’ and 3’ ends, 
respectively. CodonCode Aligner (CodonCode Corporation, Centerville, 
Massachusetts) was used to translate the DNA sequences, which were 
deposited into GenBank (KR534505). 
 
T cell stimulation and intracellular cytokine staining 
 T cell stimulation and intracellular cytokine staining were performed 
similarly to a previous detailed description [260, 261]. Briefly, 5 × 105 
cryopreserved PBMCs or LN cells were incubated for one hour at 37 °C in 200 µl 
RPMI 1640 containing 10% bovine growth serum and antibiotics with anti-CD28, 
anti-CD49d, and 10 µM the synthetic peptide SIV Gag181–189CM9 
(CTPYDINQM). In additional experiments, stimulated with 50 ng/mL of PMA and 
1 µg/ml of ionomycin (Life Technologies). Then, 10 µg/ml brefeldin A (Sigma-
Aldrich) was added, and the cells were incubated for an additional 6-8 hours at 
37 °C. Cells were washed in buffer (PBS with 10% serum), stained for surface 
expression of CD3, CD4, and CD8 markers, and fixed in 2% PFA (Electron 
Microscopy Sciences) at 4 °C. Cells were then permeabilized in wash buffer 
containing 1% saponin and stained for the expression of cytokines IFN-γ (BD 
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Biosciences). Stained cells were acquired on a custom four-laser BD Fortessa 
flow cytometer (BD Biosciences) with FACSDiva software and analyzed with 
FlowJo software (TreeStar). 
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Supplemental Figure 3.1: Gating strategy of TIGIT surface expression in 
HIV infection and associations with HIV clinical parameters. (A) 
Representative flow cytometry plots showing gating scheme to isolate CD8 and 
CD4 T cells. Gated on singlets, excluded dead cells, gated on lymphocytes, 
gated on CD3 T cells, and gated on expression of CD8 or CD4. (B) 
Representative histograms of TIGIT Isotype, TIGIT FMO and TIGIT expression 
on CD8 or CD4 T cells (HIV-infected thin solid line, HIV-uninfected dashed line, 
TIGIT isotype control shaded, and TIGIT FMO thick solid line). Graphs show the 
association of the frequency (%) of (C) TIGIT+ CD8 or (D) TIGIT+ CD4 T cells 
against clinical CD4 count for cART suppressed (left panel, open triangle, n = 20) 
and elite controllers (right panel, open squares, n = 20). Graphs show the 
association of the frequency (%) of (E) TIGIT+ CD8 or (F) TIGIT+ CD4 T cells 
against T cell activation (% CD38+HLA-DR+) for cART suppressed (left panel, 
open triangle, n = 20) and non-controllers (right panel, open circles, n = 20). 
Graphs show the association of the frequency (%) of (G) TIGIT+ CD8 or (I) 
TIGIT+ CD4 T cells against viral load log10 (copies/ml) for non-controllers (open 
circles, n = 20). Graphs show the association of the frequency (%) of (H) TIGIT+ 
CD8 or (J) TIGIT+ CD4 T cells against copies of cell associated HIV RNA per 
million CD4 T cells for L-AS (inverted open triangles, n = 19). Spearman’s rho 
tests were performed for correlations. 
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Supplemental Figure 3.2: Phenotypic assessment of TIGIT expression on 
differentiated CD8 T cell subsets. (A) Graph shows compiled frequency (%) of 
TIGIT expression on CD8 T cells subsets grouped by disease category. HIV-
uninfected (X; n = 20), acute infected (AI; open diamond; n = 24), cART 
suppressed (AS; open triangle; n = 20), elite controller (EC; open square; n = 
20), and non-controllers (NC; open circle; n = 20). Repeated-measures one-way 
ANOVA, followed by Tukey’s multiple comparisons test were used for 
comparison (*p < 0.05; **p < 0.01; ***p < 0.001). Cryopreserved PBMCs from 
chronically HIV-infected individuals were phenotyped for TIGIT expression on 
CD8 T cell subsets. (B) Representative flow cytometry plots showing gating 
scheme to isolate CD8 T cell subsets. Live lymphocytes gated for CD8 T cells, 
subset into CD45RA+ and CD45RA-, further stratified by expression of CCR7 
and CD27. (C) Representative flow cytometry plots showing CD28 expression on 
CD8 T cell subsets. (D) Representative flow cytometry plots showing TIGIT 
expression on CD8 T cell subsets. (E) Graph shows compiled frequency (%) of 
TIGIT expression on CD8 T cell subsets (n = 20). 
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Supplemental Figure 3.3: Cytokine profile of TIGIT and PD-1 expressing 
CD8 T cells. Ex vivo CD8 T cells from chronically HIV-infected individuals were 
FACS sorted into populations according to their expression of TIGIT and PD-1. 
(A) Representative flow cytometry plot of TIGIT and PD-1 expression PRE-
SORT. Gating was facilitated by isotype controls for TIGIT and PD-1. (B) 
Representative flow cytometry plots of CD8 T cells sorted into TIGIT+PD-1+, 
TIGIT+PD-1-, TIGIT-PD-1+, and TIGIT-PD-1-. No stimulation (left panel) and 
stimulated with anti-CD3 + anti-CD28 Dyanbeads for 48 hours (right panel). (C) 
Graphs show compiled data of phenotypes of sorted populations with no 
stimulation (open box) and anti-CD3 + anti-CD28 Dyanbeads (filled box) (n = 2). 
Supernatants were harvested and cytokine production was assessed 48 hours 
post anti-CD3 + anti-CD28 stimulation by high sensitivity multiplex bead array. 
(D) Graphs show concentrations of cytokines produced from sorted populations. 
 
 
 
  
	 84	
 
Supplemental Figure 3.4: Cytokine regulation of TIGIT expression. (A) 
Compiled data of HIV-infected individuals (open circle; n = 8) TIGIT expression 
frequency (%) on CD4 T cells with or without cytokine stimulation for six days. P 
values were calculated with repeated-measures one-way ANOVA, followed by 
Tukey’s multiple comparisons test (*p < 0.05). (B) Compiled data of HIV-infected 
individuals (open circle; n = 6) TIGIT expression frequency (%) on CD8 T cells 
(right panel) and CD4 T cells (left panel) after six days of IL-21 stimulation (n = 
6). P values were calculated by Wilcoxon matched-pairs signed ranked test. 
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Supplemental Figure 3.5: Effect of in vitro blockade with anti-TIGIT and 
anti-PD-L1 mAbs on HIV-specific CD8 T cell IL-2 responses. Ex vivo PBMCs 
from chronically HIV-infected individuals were stimulated with HIV Gag peptide 
pool in the presence of mAb blocking antibodies. Representative flow cytometry 
plots gated on (A) CD8 or (C) CD4 T cells, showing IL-2 responses from an HIV-
infected individual. No HIV Gag stimulation with an isotype control, HIV Gag 
stimulation with an isotype control, HIV Gag stimulation with anti-TIGIT, HIV Gag 
stimulation with anti-PD-L1, HIV Gag stimulation with dual blockade (anti-TIGIT + 
anti-PD-L1) and a positive control (anti-CD3 + anti-CD28 Dynabeads). Graphs 
show compiled data showing variation in the frequency (%) of (B) CD8 or (D) 
CD4 T cell IL-2 in responses to HIV Gag peptide pool with isotype control or mAb 
blockade; TIGIT blockade (left panel), PD-L1 blockade (middle panel), and dual 
blockade (right panel) (n = 16). 
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Supplemental Figure 3.6: rhTIGIT amino acid sequence alignment, surface 
expression, common gamma chain cytokine regulation and SIV-specific 
CD8 T cell expression. (A) Alignment shows amino acid sequences of human 
TIGIT (Hu TIGIT) and Rhesus TIGIT (Rh TIGIT). Highlighted sequences indicate 
homology between human and rhesus TIGIT. Dashes indicate gaps in alignment. 
(B) Representative flow cytometry plots depict rhTIGIT expression frequency (%) 
on CD8 T cells from PBMCs, Lymph nodes (LNs) and Spleen in representative 
non-infected and SIV-infected animals. (C) Representative flow cytometry plots 
depict rhTIGIT expression frequency (%) on naïve (N) (CD28+CD95-), effector 
memory (EM) (CD28-CD95+), and central memory (CM) (CD28+CD95+) cells 
from PBMCs, LNs and spleens in representative SIV-infected animals. Graphs 
show frequency (%) of rhTIGIT+ N, EM and CM CD8 T cells from SIV-infected 
RMs (open circle; n = 16), LNs (open square; n = 19), and spleens (open 
triangle; n = 10). P values were calculated with repeated-measures one-way 
ANOVA, followed by Tukey’s multiple comparisons test. (D) Graph shows 
compiled frequency (%) of rhTIGIT+ CD8 T cells after stimulation with IL-2, IL-12 
or IL-15 for six days. NS, no stimulation. P values were calculated with repeated-
measures one-way ANOVA, followed by Tukey’s multiple comparisons test. (E) 
Representative flow cytometry plot showing secondary antibody only against 
CM9 tetramer staining to facilitate rhTIGIT gating. (F) Representative flow 
cytometry plot showing PD-1 FMO and secondary antibody only to facilitate 
rhTIGIT and PD-1 gating. (G) Representative flow cytometry plots of rhTIGIT and 
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PD-1 expression on Mamu-A*01 SIV-Gag CM9 tetramer specific CD8 T cells. 
Graphs show compiled data of rhTIGIT and PD-1 expression frequency (%) on 
Mamu-A*01 SIV-Gag CM9 tetramer specific CD8 T cells (n = 4) from PBMC 
(open circle), LNs (open square), and spleen (open triangle). (H) Representative 
flow cytometry plots of rhTIGIT and PD-1 expression on Mamu-A*01 SIV-Tat SL8 
tetramer specific CD8 T cells. Graphs show rhTIGIT and PD-1 expression 
frequency (%) on Mamu-A*01 SIV-Tat SL8 tetramer specific CD8 T cells (n = 4) 
from PBMC (open circle), LNs (open square), and spleen (open triangle).  
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Supplemental Figure 3.7: Proliferative status of rhTIGIT expressing CD8 T 
cells in SIV infection. (A) Representative flow cytometry plots depict Ki-67 and 
rhTIGIT expression in PBMCs and Lymph nodes (LNs) from SIV-infected 
animals. (B) Graphs show frequency (%) of rhTIGIT+ Ki-67+ and rhTIGIT- Ki-67+ 
CD8 T cells in PBMCs (open circle; n = 11) and LNs (open square; n = 14) from 
SIV-infected animals. Wilcoxon matched-pairs signed- rank test was performed 
for statistical analysis (C) Representative flow cytometry plots depict Ki-67 and 
PD-1 expression in PBMCs and LNs from SIV-infected animals. (D) Graphs show 
frequency (%) of PD-1+ Ki-67+ and PD-1- Ki-67+ CD8 T cells in PBMCs (open 
circle; n = 6) and LNs (open square; n = 6) from SIV-infected animals. Wilcoxon 
matched-pairs signed- rank test was performed for statistical analysis.  
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Graphical Abstract Figure 3.1: TIGIT and PD-L1 blockade. Figure represents 
blocking the TIGIT and PD-L1 pathways with mAbs to increase HIV/SIV-specific 
CD8 T cell effector functions. 
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Graphical Abstract Figure 3.2: Enhanced “Shock and Kill” HIV cure 
strategy. Figure represents the HIV cure strategy to flush out latent HIV and 
eliminate infected cells while protecting new cells from being infected with 
cART. CD8 T cell reinvigoration with anti-TIGIT and anti-PD-L1 may be 
required to enhance CD8 T cell effector functions to eliminate infected cells 
after latency reversal. 
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CHAPTER 4 
 
GUT TISSUE-SPECIFIC DIFFERENCES IN TIGIT AND TIGIT-LIGANDS  
DURING CHRONIC cART HIV INFECTION: IMPLICATIONS FOR 
IMMUNOTHERAPY EFFICACY 
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SPECIFIC AIMS 
 
Aim I: Determine the role of TIGIT and TIGIT ligands in tissues during cART 
HIV infection 
 A: To compare the expression of TIGIT on CD8 and CD4 T cells 
 from the peripheral blood and gut in cART HIV-infected and HIV-
 uninfected subjects 
 Hypothesis: TIGIT expression will be increased on gut tissue T cells 
 compared to the peripheral blood.   
 Rationale: negative checkpoint receptors exhibit unique functions in 
 tissues and play specialized roles in regulating the immune response. 
 B: To compare the expression of TIGIT ligands from peripheral 
 blood and gut in cART HIV-infected and HIV-uninfected subjects 
 Hypothesis I: Gut tissue antigen presenting cells will have an increase of 
 the TIGIT ligand (Polio Virus Receptor (PVR)) compared to peripheral 
 blood during HIV infection.  
 Rationale: PVR is part of the nectin family that maintains intracellular 
 adherens junctions between epithelial cells and is found in gut tissue. 
 Hypothesis II: There will be an increase of Fusobacterium in the gut 
 microbiome of HIV infected individuals. 
 Rationale: Fusobacterium in the gut contains an outer membrane protein, 
 Fap2, which binds to TIGIT and protects colon tumors from immune 
 clearance and may be involved in anti-HIV T cell effector functions. 
 C: Determine the magnitude of TIGIT blockade reinvigoration and 
 relations to levels of TIGIT and TIGIT ligands in peripheral blood and 
 gut tissue 
 Hypothesis I: The magnitude of rescued response will be associated with 
 levels of TIGIT ligands.  
 Rationale: Augmented dendritic cell functions through the microbiota  
 alters CD8 T cell priming and peripheral immune function.  
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ABSTRACT 
 
 Despite the success of immunotherapy blockade of TIGIT and PD-1 
pathways in restoring anti-HIV responses ex vivo, most individuals do not exhibit 
a robust immune reinvigoration. Blood and tissue based profiling to understand 
the mechanism of TIGIT and PD-1 blockade have not widely been explored. 
Here we use immune profiling of PBMCs, RMMCs and gut microbiota 
composition from cART suppressed HIV-infected individuals to evaluate the anti-
HIV CD8 T cell blockade efficacy. We observed significant differences in TIGIT, 
PD-1, PVR, PD-L1 expression and Fusobacteria abundance from RMMCs 
compared to PBMCs in AS. The frequency of RMMC PD-L1+ pDCs correlated 
with the magnitude of IFN-γ anti-TIGIT CD8 T cell reinvigoration. The RMMC 
TIGIT+ CD8 T cells and PVR+ mDCs inversely correlated with the magnitude of 
CD107a anti-PD-L1 CD8 T cell reinvigoration. The RMMC PVR+PD-L1+ pDCs 
inversely correlated with the magnitude of CD107a combinational anti-TIGIT/anti-
PD-L1 CD8 T cell reinvigoration. There was a significant increase in the 
abundance of Fusobacteria in HIV-infected individuals. The Fusobacteria 
abundance inversely correlated with the magnitude of IFN-γ reinvigoration from 
anti-TIGIT blockade. Interestingly, anti-TIGIT blockade positively correlated with 
the beneficial gut commensal bacteria, Firmicutes and Lentisphaerae, 
abundance. These data support the idea that the relationship between RMMC 
phenotypes and microbiota abundance correlate with the magnitude of CD8 
immune reinvigoration after immunotherapy ex vivo, we identify clinically 
accessible immunotherapy treatment predictors of anti-HIV CD8 T cell responses 
to anti-TIGIT and anti-PD-L1 blockade. 
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OVERVIEW 
 
 Chronic HIV infection is associated with increased expression of negative 
checkpoint receptors (NCRs) on HIV-specific T cells in the peripheral blood that 
contribute to immune dysfunction and viral persistence [176-178, 180, 207, 208, 
262]. Cytotoxic CD8 T cells contribute significantly to the control of viral 
replication [163, 165, 169, 263-265], however, persistent viral antigens may 
stimulate CD8 T cells that subsequently leads to a progressive loss of function 
termed “T cell exhaustion” [2]. During this process, the expressions of several 
NCRs on the surface of T cells are increased, raising the threshold for T cell 
activation, and eventually results in blunted immune responses. NCR 
suppression is mediated by receptor-ligand interactions, therefore they are 
susceptible to disruption by monoclonal antibodies or recombinant proteins. We 
have shown that a surface glycoprotein, TIGIT, is overexpressed on peripheral 
CD8 T cells during chronic HIV infection and remains elevated despite effective 
viral suppression. Additionally, TIGIT marks impaired viral-specific CD8 T cells 
and in vitro blockade of TIGIT and PD-1 pathways synergistically enhancing 
virus-specific CD8 T cell effector functions [262]. In tissue, gamma chain 
cytokines, a cytokine family with the ability to regulate the expression of NCRs, 
are present at high concentrations in tissue microenvironments and may play a 
role in regulating the tissue immune responses [234, 240, 262]. For instance, 
gamma chain cytokines are enriched in the intestine and play an important role in 
maintaining T cell hemostasis [266]. Taken together, TIGIT and other potential 
NCRs that are upregulated in HIV infection may serve as potential targets for the 
reversal of T cell exhaustion both within the periphery and in the tissue.  
 Targeting NCRs is currently being evaluated as an alternative method in 
cancer therapies [267-270]. Cytotoxic T-Lymphocyte Associated Protein 4 
(CTLA-4) and Programmed Death 1 (PD-1) were the first class of NCRs targeted 
in clinical studies. Blocking PD-1 led to a dramatic increase in overall survival 
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and progression-free survival in individuals with advanced melanoma (31-44%) 
[271, 272], non-small-cell lung cancer (19-20%) [273, 274], and renal cell 
carcinoma (22-25%) [275]. Unfortunately, therapies aimed at modulating these 
pathways were only successful in a subset of individuals and associated with 
severe immune-related adverse events (IrAEs) [276, 277]. Recently, the 
immunotherapeutic focus has switched to the second tier of NCRs (TIGIT, TIM-3 
and Lag-3) that display less toxicity. In our study, we have observed a dynamic 
range of individuals who have enhanced response to HIV antigens in the 
presence of anti-TIGIT or anti-PD-L1 blockade with no association in the 
frequency of peripheral TIGIT or PD-1 T cell expressions ex vivo. Identifying 
pretreatment predictors of anti-HIV responses to anti-TIGIT and anti-PD-L1 are 
essential to future clinical application of immunotherapy in HIV cure strategies.  
 Studies characterizing immune function in the periphery have provided 
insight into HIV pathogenesis, however circulating lymphocytes only represent 
about 25% of the body’s total lymphocyte [278]. The retention of infected cells in 
tissues remains a major barrier to the eradication of HIV. Low-level viral 
replication despite cART and viral rebound as a result of treatment interruption 
suggests that tissue reservoirs harbor stable, replication-competent virus [279, 
280]. Mucosal tissues in the gastrointestinal tract are thought to play an important 
role in the acquisition and persistence of HIV. The gut contains about 85% of the 
body’s lymphoid tissue in organized lymphoid follicles (Peyer’s patches) and up 
to 90% of the body’s lymphocytes [281, 282]. During acute infection, there is a 
large abundance of highly susceptible activated CCR5-expressing CD4 T cells 
that are targeted by HIV in gut associated lymphoid tissues (GALT) [96, 281]. 
Furthermore, rectal biopsies from infected individuals on combination 
antiretroviral therapy (cART) show stable HIV RNA and DNA levels up to two-fold 
higher than in the blood [283]. Characterizing gut lymphocytes during chronic HIV 
infection is critical to understanding the pathogenesis of HIV and developing 
curative strategies. 
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 In addition to lymphocytes, antigen-presenting cells such as dendritic cells 
(DCs) also play a fundamental role in inducing immunity and maintaining immune 
tolerance [284]. DCs can be divided into different subsets: myeloid-derived 
dendritic cells (mDCs), which express CD11c, and plasmacytoid dendritic cells 
(pDCs), which express CD123 [285]. Receptor-ligand interactions during direct 
cell-to-cell contact and cytokines secreted from DCs ultimately determine the fate 
of T cells. TIGIT and PD-1 on T cells interact with their respective ligands on 
DCs, Poliovirus receptor (PVR) [224] and programmed death-1 ligand (PD-L1) 
[286] respectively, to prevent T cell activation and promote tolerance. DCs can 
be found in the lamina propria, small and large intestine are known to control 
specialized aspects of tissue immunity [287]. Characterizing the role of TIGIT-
ligand expressing DCs in the intestine will help increase our understanding of 
intestinal immunity during chronic HIV infection. 
 The human intestinal microbiota plays an intricate role in the development 
and function of the systemic immune system [145, 146]. Recent studies have 
showed the role of intestinal microbiota and its ability to promote cancer 
therapies through the targeting of NCR pathways. Bacteroidetes was reported to 
enhance the efficacy of CTLA-4 blockade and elimination of metastatic 
melanoma in mice and humans [288]. In a similar study, anti-tumor immune 
effects by CD8 T cell was restored upon the blockade of PD-L1 and the resulting 
tumor clearance relied on gut Bifidobacterium colonization [289]. Another 
bacterium, Fusobacteria, was shown to associate with T cell responses in 
malignancy. Fusobacteria is a core member of the human anaerobic oral 
microbiota and is non-native to the human gut. However, overabundance of 
Fusobacteria in the gut has been associated with the promotion of colonic tumor 
formation and shown to inhibit immune function through Fap2, a membrane 
protein, through its interaction with TIGIT [290, 291]. Identifying microbiome 
composition during chronic HIV infection may inform anti-viral immunity and 
responsiveness to anti-TIGIT and anti-PD-L1 immunotherapy. 
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 In the present study, we aim to explore the correlation between 
rectosigmoid mucosal mononuclear cells (RMMCs) phenotypes with their 
peripheral blood mononuclear cell (PBMC) counterparts. Additionally, we 
characterized the microbiome communities of cART suppressed HIV-infected 
individuals and compared them to matched HIV-uninfected individuals and 
explored if the change in HIV-associated gut microbial abundance was 
associated with the changes in CD8 T cell phenotype and function. By profiling 
matched peripheral immune responses of CD8 T cells to immunotherapeutic 
blockade, we found motivating correlates of efficacy. The magnitude of 
reinvigoration correlated with ligand phenotypes from RMMC APCs and 
abundance of Fusobacteria. These data suggest a potential approach to HIV 
eradication through CD8 T cell functional modulation with gut microbial 
manipulation. 
MATERIALS AND METHODS 
 
Human subjects 
 Patients and specimens: For this study, fresh rectosigmoid biopsies from 
the Gut Biopsy Assessment Study (PI: Ndhlovu) were conducted at HICFA. 
Twelve gut biopsies and peripheral blood were obtained from each participant as 
outlined below. The Queen’s Medical Center Research and Institutional Review 
Committee have approved this study. 
 Inclusion Criteria: HIV-infected participants: HIV infection as documented 
by ELISA and/or confirmed by other standard assay at any time prior to study 
entry, received continuous antiretroviral (ARV) medication for >6 months with HIV 
RNA viral loads <48 copies/ml, and CD4 count within past 6 months >200 
cells/ml. HIV-uninfected participants: Negative HIV ELISA test. All subjects for 
the study must be >50 years of age and plan to undergo a screening 
colonoscopy as standard of care, are able and willing to provide informed 
consent, and have the following laboratory parameters documented prior to study 
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entry: hemoglobin >12.0; absolute neutrophil count >500/µL; platelet count 
>40,000/µL; PT/PTT within normal limits. 
 Exclusion Criteria: All subjects with history of cardiac condition, current or 
history of past malignancies excluding basal cell carcinoma and Kaposi’s 
sarcoma restricted to the skin, history of bleeding tendency and use of 
anticoagulants, use of any immunomodulators, investigational therapies and any 
vaccination within 30 days of study entry, requirement of acute therapy for other 
AIDS-defining or other serious illnesses within fourteen days prior to study entry, 
history of other chronic illnesses except subjects on stable physiologic 
replacement therapy for low testosterone or thyroid levels, current active 
substance or alcohol abuse, pregnancy, breast-feeding, intention to become 
pregnant during the course of the study, any condition that places subject at 
increased risk of complications from colonoscopy or biopsies, and acute or 
chronic diarrhea or history of enteropathies. 
 
Peripheral Blood Mononuclear Cells Isolation 
 Venous whole blood was collected in plastic whole blood tubes with spray-
coated K2EDTA (BD Biosciences, San Jose California) separated within 30 
minutes of the blood draw. PBMCs were isolated using Ficoll-Hypaque (Sigma-
Aldrich, Dorset, United Kingdom) density gradient centrifugation. Separated 
PBMCs were cryopreserved or directly used for phenotypic and polyfunctional 
analysis. 
 
Isolation of rectosigmoid mucosal mononuclear cells from fresh gut biopsy 
 To generate a single cell suspension of rectosigmoid mucosal 
mononuclear cells (RMMCs), nine to twelve endoscope-obtained tissue 
fragments were washed thoroughly with cRPMI (RPMI 1640 medium; (Hyclone, 
Logan, Utah) supplemented with 10% fetal bovine serum (FBS) (Hyclone), 1% 
penicillin-streptomycin (Hyclone), 10 mM HEPES (Hyclone), 2 mM L-glutamine 
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(Hyclone) and digested with collagenase II (Sigma-Aldrich, Dorset, United 
Kingdom) solution, and filtered through a 70 µm nylon mesh. Leftover undigested 
tissue was re-digested with collagenase II solution. RMMCs were washed PBS + 
2% FBS (Hyclone) and re-suspended for flow cytometry analysis. 
 
Antibodies and flow cytometric analysis 
 Freshly obtained or frozen PBMCs and isolated RMMCs were washed 
with PBS + 2% FBS (Hyclone). Cells were stained for viability with a Live/Dead 
aqua amine reactive dye (AARD; Invitrogen, Carlsbad, California), then 
incubated with panels of fluorochrome conjugated anti-human monoclonal 
antibodies (mAbs). The following directly conjugated mAbs used in this study 
were obtained from BD biosciences (San Jose, California): Alexa700-conjugated 
CD4 (clone: RPA-4T), mAb obtained from Beckman Coulter (Fullerton, 
California) ECD-conjugated anti-CD3 (UCHT1). mAbs obtained from eBioscience 
(San Diego, California) PE-Cy7-conjugated anti-CD28 (CD28.2), PerCP-eFluor 
710-conjugated anti-TIGIT (MBSA43), PE-conjugated anti-TIGIT (MBSA43), 
Mouse IgG1 Kappa isotype control PerCP-eFluor 710 (P3.6.2.8.1), mouse IgG1 
K isotype control PE (P3.6.2.8.1). Qdot 605-conjugated anti-CD8 (3B5) was 
obtained from Invitrogen (Carlsbad, California). Flow analyses were performed 
on a custom 4-laser BD LSRFortessa. Between 100,000 to 500,000 lymphocyte 
events were collected for each sample. Isotype controls or fluorescence minus 
one (FMO) samples were prepared to facilitate gating. Anti-mouse or anti-rat 
IgG-coated beads (BD Biosciences) were individually stained with each 
fluorochrome-conjugated antibody and used for software-based compensation. 
Data were analyzed using Flowjo Software version 9.5 (Treestar, Ashland, 
Oregon). 
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Anti-TIGIT and anti PD-L1 monoclonal antibodies 
 The TIGIT antibody clones 11G11 were generated in HuMab mice [257, 
258] immunized with a TIGIT-Fc fusion protein and selected based on their high 
affinity for TIGIT and ability to block TIGIT/PVR interaction. Clone 11G11 is a 
fully human IgG1 antibody that was engineered to contain a well-characterized 
set of mutation in the Fc that eliminate FcR interaction [259]. The anti-human PD-
L1 antibody, clone 12A4, is a fully human IgG4 (S228P) that was generated in 
HuMab mice immunized with PD-L1-Fc. This antibody was selected based on its 
ability to block the binding of PD-L1 to both PD-1 and CD80.  
 
Ex vivo antigen stimulation with antibody blockade assay 
 Cryopreserved PBMCs were rapidly thawed and seeded at one million 
cells per stimulation condition with isotype control antibody (IgG1), single or 
combination of purified anti-TIGIT and/or anti-PD-L1 and stimulated with/without 
pooled HIV Gag peptides. The HIV clade B Gag peptide pool consists of 123 
overlapping ~15mer peptides designed to elicit broad T cell responses (NIH). 
After a three-day incubation at 37°C with 5% CO2, cells were washed and 
supplemented with media plus IL-2 for 2 days. On day five, cells were re-
stimulated overnight with pooled HIV Gag peptides and the same blockade 
conditions along with APC-conjugated CD107a (BD Biosciences, Clone H4A3), 5 
µg/ml brefeldin A and 5 µg/ml monensin (Sigma-Aldrich) culture media. After 
stimulation, the cells were washed and stained for viability with AARD, cultured 
with surface phenotype panel against Qdot605-conjugated CD8 (Invitrogen), 
PerCP-eFluor 710-conjugated TIGIT (eBioscience) or an isotype control 
antibody, followed by intracellular staining of ECD-conjugated CD3 (Beckman 
Coulter), FITC-conjugated IFN-γ (BD Bioscience, Clone 25723.11), and 
Alexa700-conjugated TNF-α (eBioscience, Clone MAb11), acquired on the flow 
cytometer then analyzed as above. 
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Bacterial 16S rRNA sequencing 
 One to two tissue fragments (50-100mg) were collected from rectosigmoid 
biopsies in cRPMI 10% without 1% penicillin-streptomycin and re-suspended and 
lysed in beta mercaptoethanol-added lysis buffer. Total DNA and RNA was 
isolated using AllPrep DNA/RNA/miRNA Universal kit (Qiagen), followed by 
DNA/RNA yield analysis using NanoDrop 2000 UV-Vis Spectrophotometer. We 
amplified 7 of 9 hypervariable regions in the bacterial 16S rRNA gene with PCR 
primers designed to target more than 805 sequences in the Greengenes 
database [292, 293] using Ion 16S Metagenomics Kit (Ion Torrent, Life 
Technologies). Amplified DNA were subsequently purified, ligated with 
sequencing adapters, and quantified. 16S libraries were templated using the Ion 
PGM™ Template Kit (Ion Torrent, Life Technologies) and sequenced on the Ion 
Torrent PGM instrument (Ion Torrent, Life Technologies). The sequence reads 
were analyzed using the Metagenomics workflow in the Ion Reporter™ software 
and plotted against the Greengenes database. 
 
Statistical analysis 
 The repeated-measures, one-way ANOVA followed by Tukey’s multiple 
comparison, Mann-Whitney U Tests, Wilcoxon matched-pairs signed ranked and 
the Spearman’s rho test were performed using Graphpad release 5.0d 
(Graphpad Software, San Diego, California) or SPSS 22.0 (IBM, Armonk, New 
York) with the statistical significance of the findings set at a p value of less than 
0.05. Measures of central tendency are expressed as medians and interquartile 
ranges (IQRs; given in the form 25th percentile, 75th percentile).  
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RESULTS 
 
Differential expression pattern of TIGIT and PD-1 from matched rectal 
mucosal mononuclear cells and peripheral blood mononuclear cells. 
 Chronic HIV infection leads to NCRs-mediated T cell exhaustion that 
actively inhibits antigen-specific T cell responses both in the periphery and 
tissues [178, 262]. In this study, we profiled the expression of TIGIT and PD-1 on 
T cells from rectal mucosal mononuclear cells (RMMCs) and peripheral blood 
mononuclear cells (PBMCs) from cART suppressed HIV-infected (AS) and 
compared these results with age-matched HIV-uninfected (HD) individuals (Table 
4.1, Figure 4.1A-G). We observed significantly higher TIGIT+PD-1+ CD8 T cells 
from RMMCs compared to PBMCs (Median: 33% vs. 14.2% respectively, p = 
0.046) from the AS individuals (Figure 4.1B right panel). When comparing 
RMMCs and PBMCs from AS individuals, we observed significantly higher 
TIGIT+ CD4 T cells (39.7% vs18% respectively, p = 0.015), PD-1+ CD4 T cells 
(71.8% vs. 36.9% respectively, p = 0.015) and TIGIT+PD-1+ CD4 T cells (35.3% 
vs. 6.8% respectively, p = 0.015) (Figure 4.1C). We did not observe any 
significant differences in T cell expression of TIGIT or PD-1 from RMMCs 
compared to PBMCs from HD individuals (Figure 4.1E-F). Between AS and HD 
RMMCs, we observed significantly lower PD-1+ CD8 T cells (AS 46% vs. HD 
61.6%, p = 0.048) and significantly higher TIGIT+ CD4 T cells (AS 39.7% vs. HD 
28.8%, p = 0.048) (Figure 4.1G). These data suggest that despite viral 
suppression, TIGIT expression remains higher on RMMC-resident T cells 
compared to those found in the periphery and may have a dominant role in 
regulating T cell immune response while maintaining CD4 T cell viral persistence 
in the gut.  
 
PVR and PD-L1 expression profile varies on antigen presenting cells by 
anatomical location. 
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 Effective adaptive immune responses depend on the efficient presentation 
of antigen by professional antigen-presenting cells (APCs). Dendritic cells (DCs) 
are sentinel APCs that capture antigen, migrate through tissues and produce 
cytokines that impact T cell maturation and activation [294]. We next assessed 
the expression of poliovirus receptor (PVR) and programmed death 1 ligand (PD-
L1), ligands to TIGIT and PD-1, respectively, on dendritic cell subsets from 
RMMCs and PBMCs from AS individuals and compared these results with HD 
individuals (Table 4.1, Figure 4.2A-G). When comparing RMMCs to PBMCs from 
AS individuals, we observed significantly lower PVR+ mDCs (78.6% vs. 93.4% 
respectively, p = 0.015), significantly higher PD-L1+ mDCs (80.3% vs. 28.9% 
respectively, p = 0.015) and significantly higher PVR+PD-L1+ mDCs (87.5% vs. 
28.7% respectively, p = 0.015) (Figure 4.2B). When comparing RMMCs to 
PBMCs from AS individuals, we observed significantly higher PVR+ pDCs 
(93.5% vs. 54.6% respectively, p = 0.015), PDL1+ pDCs (66.4% vs. 24.2% 
respectively, p = 0.015), and PVR+PD-L1+ pDCs (50.3% vs. 20.8% respectively, 
p = 0.031) (Figure 4.2C). We did not observe any significant differences in 
dendritic cell expression of PVR or PD-L1 in RMMCs compared to PBMCs from 
HD individuals (Figure 4.E-F). When comparing AS to HD RMMCs, we observed 
significantly higher PD-L1+ mDCs (80.3% vs. 62.75% respectively, p = 0.0101) 
and significant increase of PVR+PD-L1+ mDCs (87.5%vs 64.1% respectively, p 
= 0.025) (Figure 4.2G). Taken together, these data suggest that antigen-
presenting cells in the gut may be interacting with T cells to suppress immune 
function through ligand-receptor NCR interactions. 
 
Group differences in the microbiome distribution among cART-suppressed 
HIV-infected and HIV-uninfected individuals. 
 The intricate balance between the host immune system, eliminating 
pathogens while maintain self-tolerance is essential to overall immune health. 
Intestinal microbiota has been considered an important modulator of immune 
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responses, specifically T cell immune activation in malignancies [294]. We 
assessed the microbiome profiles from rectosigmoid biopsies collected from AS 
and compared these results with HD individuals. Microbiome comprehensive 
identification of 16s ribosomal RNA sequencing was determined by pipeline 
using the Greengenes database [292, 293]. We observed significantly higher 
levels of Fusobacteria in AS compared to HD individuals (0.15% vs. 0.0024% 
respectively, p = 0.03) (Table 4.2; Figure 4.3-B). Although not statistically 
significant, during the comparative phyla analysis between AS and HD 
individuals, we observed a lower abundance of Firmicutes (33.36% vs. 44.95% 
respectively) and Bacteroidetes (28.75% vs. 20.21%) and a higher abundance of 
Actinobacteria (0.23% vs. 0.015%) (Table 4.2; Figure 4.3A). The enrichment of 
the pathogenic Fusobacteria and alterations to the intestinal microbial community 
during chronic cART-suppressed HIV infection may drive the systemic immune 
dysfunction in AS individuals. 
 
Magnitude of TIGIT and PD-L1 monoclonal antibody blockade 
reinvigoration and periphery/tissue parameters. 
 In chronic HIV infection there is an increase in the active inhibition of the 
CD8 T cell effector functions that induces a progressive loss of CD8 T cell 
effector activity. PD-1 blockade leads to a dramatic increase in overall survival 
and progression-free survival in individuals with various malignancies [271-275]. 
However, subsets of individuals remain unresponsive to this method of 
immunotherapy. In the current study, we assessed the anti-HIV immune 
reinvigoration of peripheral CD8 T cells in the presence of anti-TIGIT and anti-
PD-L1 blocking antibodies to matched rectosigmoid biopsy immune cell 
phenotypes and microbiome composition. We observed an increased in the fold 
change of interferon gamma (IFN-γ) RMMC responses to single anti-TIGIT and 
anti-PD-L1 blockade. We observed an increased fold change of interferon 
gamma (IFN-γ) CD8 T cell HIV Gag responses to single anti-TIGIT and anti-PD-
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L1 blockade, and a higher fold change increase was observed in the combined 
anti-TIGIT plus anti-PD-L1 monoclonal antibodies (mAb) blockade (Figure 4.4A, 
4.4B left panel, Combo). Similar trend was also observed in CD107a, lysosomal- 
associated membrane protein-1 marker of cellular degeneration, CD8 T cell Gag 
responses (Figure 4.4A, 4.4B right panel).  
 Next, we explored the correlation between RMMC T cells and antigen 
presenting DCs phenotypes and fold change in the cell restoration marker after 
antibody blockade. We observed a significant correlation between higher RMMC 
PD-L1+ pDCs and increased fold change of IFN-γ+ CD8 T cell Gag responses in 
the presence of anti-TIGIT blockade (p = 0.012, rho = 0.89) (Figure 4.4C). We 
also observed a significant inverse correlation between higher RMMC TIGIT+ 
CD8 T cells and PVR+ mDCs and decreased fold change of CD107a+ CD8 T 
cells HIV Gag responses in the presence of anti-PD-L1 blockade (p = 0.023, rho 
= -0.85; p = 0.034, rho = -0.79 respectively) (Figure 4.4D). A significant inverse 
correlation was also observed between higher RMMC PVR+PD-L1+ pDCs with 
decreased fold change of CD107a+ CD8 T cell Gag responses in the presence of 
the combination of anti-TIGIT plus anti-PD-L1 blockade (p = 0.048, rho = -0.78) 
(Figure 4.4E).  
 Finally, we evaluated the magnitude of anti-HIV T cell reinvigoration by 
mAb blockade relative to gut microbial abundance. Our study showed that 
decreased IFN-γ+ CD8 T cell HIV Gag responses by TIGIT blockade was 
negatively correlated with higher Fusobacteria abundance (p = 0.034, rho = -
0.821) and with lower abundance of two non-pathogenic commensals, 
Lentisphaerae and Firmicutes (p=0.014, rho= 0.85 and p=0.04, rho= 0.78, 
respectively) (Figure 4.4F). Taken together, these data imply that the peripheral 
TIGIT and PD-L1 blockade efficacy may be affected by gut tissue immune cells 
and gut dysbiosis in cART-suppressed HIV-infected individuals.  
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DISCUSSION 
 
 Here we report several findings relevant to the understanding of the 
peripheral anti-HIV CD8 T cell responses to anti-TIGIT and anti-PD-L1 blockade 
in cART-suppressed individuals chronically infected with HIV. We (1) unveiled 
the expression of TIGIT in the context of PD-1 in the rectosigmoid mucosa and 
demonstrate compartmental differences within HIV-infected and HIV-uninfected 
individuals, (2) evaluated the expression of TIGIT and PD-1 ligands, PVR and 
PD-L1 respectively, from rectosigmoid mucosal DC subsets and demonstrate 
differences in HIV-uninfected individuals, (3) explored the microbiome 
composition and show differences in the bacterial abundance with the 
colonization of pathogenic Fusobacteria in HIV-infected individuals, and (4) 
demonstrate the magnitude of peripheral anti-HIV CD8 T cell immune 
reinvigoration by anti-TIGIT and anti-PD-L1 blockade correlates with bacterial 
abundance and immunological tissue parameters. 
 Preventing the establishment of viral reservoirs in the gut has been shown 
to result in sustained simian immunodeficiency virus (SIV) control and immune 
reconstitution after cART is withdrawn [295]. Blocking α4β7, an integrin involved 
in lymphocyte homing and retention, prevents the establishment of virus in the 
gut during acute infection and leads to decreased viral loads in a rhesus 
macaque model of HIV/AIDS [296]. The exact mechanism of control is unknown 
and whether it translates to humans that are chronically infected has yet to be 
determined. However, these data suggest that targeting the gut to improve 
immune function may prove to be an effective means of eliminating virus and 
bringing us closer to a functional or sterilizing cure. The higher frequency of 
RMMC TIGIT+PD-1+ CD8 T cells may be contributing to T cell dysfunction and 
viral persistence in the gut of HIV-infected individuals. Unfortunately, due to 
limited number of RMMCs derived from the rectosigmoid biopsies, we were 
unable to perform additional functional studies to evaluate the effects of TIGIT 
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and PD-L1 blockade on HIV-specific CD8 T cells in the gut. Future studies will be 
aimed at evaluating the functional capacity of exhausted T cells in the gut. 
 Interestingly, we observed a higher frequency of RMMC PD-1+ CD8 T 
cells from HIV-uninfected compared to HIV-infected individuals. PD-1 has been 
suggested to play a key role in intestinal tolerance. One study evaluated the 
effects of intestinal epithelium-specific antigen in PD-1-/- transgenic mice and 
observed a fatal CD8 T cell-mediated inflammatory response as well as the 
destruction of epithelial barriers only in the intestine [297]. Furthermore, Rhesus 
macaques display a decrease in RMMC PD-1+ CD8 T cells after SIV infection 
[298]. Our data suggests that HIV-infected individuals have increase in 
proinflammatory RMMC PD-1- CD8 T cells that may contribute to the persistence 
of HIV-induced gut damage. 
 TIGIT has been described to mark a subset of highly suppressive 
regulatory CD4 T cell (Tregs) [228, 299, 300]. Additionally, TIGIT+ Tregs have 
been reported to selectively inhibit proinflammatory T helper type 1 (Th1) and T 
helper type 17 (Th17), which is an important CD4 T cell subsets in maintaining 
gut immunity and integrity [228]. Moreover, Tregs also express PD-1 on the 
surface of activated Tregs in lymph nodes in the blood [301, 302]. Furthermore, 
memory CD4 T cells expressing multiple NCRs are enriched in inducible HIV 
DNA [303]. We observed an enrichment of TIGIT+, PD-1+ and TIGIT+PD-1+ 
CD4 T cells in RMMCs compared to PBMCs with a significantly higher RMMC 
TIGIT+ CD4 T cells in HIV-infected compared to HIV-uninfected individuals. Our 
data indicates that the TIGIT+ CD4 T cells may be further contributing to the HIV-
induced gut damage in addition to viral persistence. Our future panels will be 
modified to include the transcription factor forkhead box P3 (FOXP3), Helios and 
surface receptor CD25, CD27, and CD45RA to better characterize Treg and 
memory CD4 T cell subsets. 
 Dendritic cells bridge the innate and adaptive immune systems and have 
the potent ability to induce immune tolerance through receptor-ligand interactions 
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and secreted cytokines to prevent immune activation and autoimmunity while 
maintaining immune hemostasis [285]. PD-1:PD-L1 interactions can directly 
inhibit T cell proliferation and survival [304]. While PD-L1+ antigen presenting 
cells have been implicated in several histolytic and dendritic cell disorders [305], 
during HIV infection there is an increase of peripheral PD-L1+ DCs and correlate 
directly with viral load [306, 307]. Furthermore, TIGIT:PVR interact bidirectionally 
to induce T cell dysfunction while promoting mature immunoregulatory DCs 
[221]. Our observations of the expansion of RMMC PD-L1+ and PVR+PD-L1+ 
mDCs during HIV infection indicate that DCs could be selectively supporting the 
persistence of dysfunctional TIGIT+ and PD-1+ T cells in the gut and periphery. 
 From analysis of the gut microbiome, we detected Fusobacteria presence 
in all HIV-infected individuals and HIV-uninfected controls, however the relative 
abundance was significantly higher in HIV-infected subjects compared to their 
matched controls. Fusobacterium, the main member of Fusobacteria phyla, is an 
anaerobic gram-negative species frequently isolated from the oral cavity of both 
healthy and diseased individuals, and is associated with periodontal disease 
[308, 309]. 
 While the Fusobacteria are non-native to the human gut, their presence 
are detected and associated with colorectal cancer and promotes colonic tumor 
formation [291], suggesting that despite the distance from their natural oral niche, 
Fusobacteria possess the ability to translocate and colonize other organs, 
including the gut. The route in which Fusobacteria might translocate from the oral 
cavity to gut includes transient bacteremia that occurs following tooth brushing 
[310]. Normally, bacterial clearance is conducted by the liver, however in 
individuals with impaired liver function due to side effects of cART treatment, the 
liver’s ability to clear peripheral bacteremia can be impaired [310].  
 In HIV infection, greater prevalence of Fusobacteria was identified from 
subgingival plaque from HIV-infected patients compared to HIV-uninfected 
individuals with chronic periodontitis [309]. HIV-infected individuals also possess 
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a higher risk of periodontal attachment loss that can lead to chronic periodontal 
disease, which is reported to be higher in these individuals compared to the 
general population [311, 312]. The combination of higher oral Fusobacteria 
colonization with increased risk of periodontal disease put HIV-infected subjects 
at higher risk for Fusobacteria bacteremia and Fusobacteria colonization in 
different organs that may be followed by systemic and local immune reaction to 
the bacterial colonization. 
 The higher gut Fusobacteria abundance in HIV-infected individuals in our 
study suggests a special HIV-related condition that can drive the bacterial 
translocation from its original habitat to the gut mucosa. In HIV infection, the high 
concentration of CCR5-expressing T-cells causes gut tissue to be the earliest 
mucosal target and a site for CD4 T-cell depletion causing epithelial injury that 
leads to microbial translocation and gut dysbiosis [152, 313]. Early introduction to 
cART only partially restores gut integrity, causing persistent disturbance in 
intestinal homeostasis and driving the microbial translocation immune activation 
in chronic HIV patients. [314, 315]. Our current study supports the hypothesis 
that gut microbial abundance in HIV-infected individuals differs from HIV-
uninfected controls with a significantly higher abundance of Fusobacteria. The 
presence of Fusobacteria may trigger local and systemic immune activation in 
these patients suggesting a creation of mechanistic pathological cycle between 
gut dysbiosis, disrupted gut hemostasis and immune activation/dysfunction that 
persists despite viral suppression. 
 T cells depend on environmental nutrient composition and dynamic 
metabolic reprogramming to perform essential effector and memory functions  
[316]. In mice, chronic lymphocytic choriomeningitis virus (LCMV) infection 
results in a PD-1 mediated repression of glycolytic and mitochondrial metabolism 
in CD8 T cells [317]. Fusobacteria Fap2 engagement of TIGIT in the gut may 
induce metabolic reprograming that is not restored by peripheral anti-TIGIT 
blockade. Normal non-diabetic glucose concentrations in the periphery are 100 
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fold lower than in the gut, implying altered immunometabolism requirements in 
different anatomical sites throughout the body [318, 319]. As a result, the anti-
TIGIT blockade may require nutrient composition similar to the tissues where the 
T cell is primed and TIGIT is engaged. In the future, it would be interesting to 
evaluate the metabolic demands in the presence of Fusobacteria Fap2 in 
mitochondrial stress assays. 
 Lymphocytes are constantly circulating throughout our bodies and traffic 
from the periphery through secondary lymphoid organs and tissues in search of 
cognate peptide-MHC complexes [320]. Priming of T cells depends on 
interactions between DCs in the lymph node and tissue microenvironments which 
ultimately influence peripheral immune tolerance [321]. Ligation of TIGIT has 
been shown to inhibit the priming of CD4 and CD8 T cells [223]. Studies using 
specific-pathogen-free mice have been conducted to understand the role of the 
microbiome in influencing the priming and activation of the systemic host immune 
system  [322]. Our data suggests that gut microbiota and tissue immune 
parameters can predict peripheral immune response to immunotherapy..    
 The identification and treatment of Fusobacteria from rectal biopsies may 
be required as an anti-TIGIT pre-treatment predictors. Moreover, dietary 
supplements with probiotics [323] or fecal microbiota transplants [324] maybe be 
useful as adjunctive therapy to “reboot” the gut microbial ecosystem before anti-
TIGIT therapy. Furthermore, it would be clinically relevant to extend our findings 
to oncologic therapies targeting TIGIT and PD-1 pathways.  
 In summary, these data provide a comprehensive analysis of TIGIT and 
TIGIT ligands in the gut of HIV-infected and HIV-uninfected individuals and 
identifies potential novel predictive biomarkers for identifying anti-HIV CD8 T cell 
reinvigoration by TIGIT and PD-L1 blockade. Results from this study will help 
characterize gut T cells during chronic aviremic HIV infection and allow for a 
better understanding of the specialized role of TIGIT plays in regulating distinct 
aspects of peripheral immunity. A better understanding of these facets of HIV 
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immunity will aid in the development of more effective immune-based therapies 
for the eradication of HIV.  
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TABLES 
  
Table	4.1:	Participant	Characteristics
HIV+	cART	
Suppressed	
(AS;	n	=	7)
HIV-Uninfected	
Donors	
(HD;	n	=	5) p	value
Parameters Median	(IQR) Median	(IQR)
Age	(Years) 57	(52,	62) 53	(51,	58) 0.4533
CD4	T	cell	Count	(cells/mm3) 560	(387,	922) N/A
HIV	Viral	Load	(copies/ml) <20 N/A
cART	Therapy Yes N/A
Gender	Distribution
Male	%	(no.) 85	(6) 80	(4) 0.998
N/A=	Not	Applicable
cART:	Combinational	Antiretroviral	Therapy
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Figure 4.1: TIGIT and PD-1 are upregulated on mucosal mononuclear T 
cells derived from rectosigmoid biopsies. RMMCs and PBMCs from cART 
suppressed HIV-infected and HIV-uninfected individuals were stained for viability 
and antibodies against CD3, CD4, CD8, TIGIT and PD-1. Representative flow 
cytometry plots of matched RMMCs and PBMCs gated on live CD3+ 
lymphocytes, from representative (A) HIV-infected and (D) HIV-uninfected 
individuals. Compiled data comparing the differences of TIGIT and PD-1 
expression on CD8 T cells from RMMCs and matched PBMCs of (B) HIV-
infected (n = 7) and (E) HIV-uninfected (n = 5). Compiled data comparing the 
differences of TIGIT and PD-1 expression on CD4 T cells from RMMCs and 
matched PBMCs of (C) HIV-infected (n = 7) and (F) HIV-uninfected (n = 5). (I) 
Compiled data of PD-1+ CD8 T cells and TIGIT+CD4 T cells from RMMCs from 
HIV-infected (n = 7) and HIV-uninfected individuals (n = 5). The p-values were 
calculated using Wilcoxon matched-pairs signed ranked test for matched pairs 
and Mann-Whitney U test for cohort comparison. 
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Figure 4.2: PVR and PD-L1 were differentially expressed on dendritic cell 
subsets from mucosal mononuclear T cells derived from rectosigmoid 
biopsies. RMMCs and PBMCs from cART suppressed HIV-infected and HIV-
uninfected individuals were stained for viability and antibodies against CD3, CD7, 
CD14, CD19, CD20, CD11b, CD11c, CD123, HLA-DR, PVR, PD-L1. 
Representative flow cytometry plots of matched RMMCs and PBMCs gated on 
live CD3-, CD19-, CD7-, CD20-, CD14-, HLA-DR+ population from representative 
(A) HIV-infected and (D) HIV-uninfected individuals. Compiled data comparing 
the differences of PVR and PD-L1 expression on mDCs from RMMCs and 
matched PBMCs of (B) HIV-infected (n = 7) and (E) HIV-uninfected (n = 5). 
Compiled data comparing the differences of PVR and PD-L1 expression on 
pDCs from RMMCs and matched PBMCs of (C) HIV-infected (n = 7) and (F) HIV-
uninfected (n = 5). (I) Compiled data of PD-L1+ mDCs and PVR+PD-L1+ mDCs 
from RMMCs from HIV-infected (n = 7) and HIV-uninfected (n = 5) individuals. P 
values were calculated using Wilcoxon matched-pairs signed ranked test for 
matched pairs and Mann-Whitney U test for cohort comparison 
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Figure 4.3: Microbiome compositions among HIV-infected and HIV-
uninfected individuals. RNA was isolated from rectosigmoid biopsies and 
sequenced for microbial 16S rRNA from cART suppressed HIV-infected (HIV+) 
and HIV-uninfected (HIV-) individuals. Sequences were mapped to the 
Greengenes Database. (A) Compiled data of percent mapped reads of 
microbiome abundance at the phyla level, grouped as HIV+ (n = 7) and HIV- (n = 
5). (C) Compiled data of Fusobacteria relative abundance as percent mapped 
reads, grouped as HIV+ (n = 7) and HIV- (n = 5). P values were calculated using 
Mann-Whitney U test. 
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Figure 4.4: Peripheral CD8 T cell immune restoration is associated with 
RMMC phenotypes or microbiome abundance. PBMCs were stimulated with a 
HIV Gag peptide pool in the presence, absence or combination of anti-TIGIT 
and/or anti-PD-L1 monoclonal blocking antibodies or IgG1 isotype and assessed 
for the production of interferon gamma (IFN-γ) and degranulation (CD107a). (A) 
Representative flow cytometry plots gated on Live CD3+ CD8 T cells, showing 
IFN-γ (solid gate) and CD107a (dashed gate) responses from two cART 
suppressed HIV-infected individuals. No HIV Gag stimulation with an isotype 
control, HIV Gag stimulation with an isotype control, HIV Gag stimulation with 
anti-TIGIT, HIV Gag stimulation with anti-PD-L1, HIV Gag stimulation with dual 
blockade (anti-TIGIT + anti-PD-L1) (B) Graphs show compiled data of the fold 
change of IFN-γ (B, right panel) and CD107a (B, left panel) in the presence of 
blocking mAbs normalized to HIV Gag stimulation with IgG1 isotype. Matched 
phenotypes from RMMCs were compared with the reinvigoration of PBMC CD8 T 
cells effector functions by mAb blockade. (C) Graph shows correlation of the 
frequency (%) of PD-L1+ pDCs from RMMCs against the fold change of anti-HIV 
Gag IFN-γ CD8 T cells with anti-TIGIT blockade. (D) Graph shows correlation of 
the frequency (%) of TIGIT+ CD8 T cells (D, left panel) PVR+ mDCs (D, right 
panel) from RMMCs against the fold change of anti-HIV Gag CD107a CD8 T 
cells with anti-PD-L1 blockade. (E) Graph shows correlation of the frequency (%) 
of PVR+PDL1+ pDCs from RMMCs against the fold change of anti-HIV Gag 
CD107a CD8 T cells with dual blockade. (F) Graph shows correlation of the 
relative abundance of Fusobacteria (F, left panel), Firmicutes (F, middle panel) 
and Lentisphaerae (F, right panel) from rectosigmoid biopsies against the fold 
change of anti-HIV Gag IFN-γ CD8 T cells with anti-TIGIT blockade. P values 
were calculated using values were calculated using one-way ANOVA, followed 
by Tukey’s multiple comparisons test, Spearman’s rho test was performed for 
correlations. 
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GRAPHICAL ABSTRACT 
 
 
 
 
 
 
 
Graphical Abstract Figure 4.1: Potential pretreatment predictors of 
response to TIGIT blockade in enhanced “shock and kill” HIV cure 
strategies. Figure represents evaluating gut immune parameters and gut 
microbiome of individuals before enhanced “shock and kill” eradication 
strategies using TIGIT and PD-L1 blockade.  
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CHAPTER 5 
DISSERTATION SUMMARY AND FUTURE PERSPECTIVES  
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DISSERTATION SUMMARY 
 
 An estimated 36 million individuals have died from HIV/AIDS since the first 
cases were reported in 1981 with roughly 36 million individuals currently living 
with HIV at the end of 2015 worldwide. Despite the significant advancements in 
antiretroviral therapy, the understanding of viral pathogenesis and immunological 
host interactions gained from several decades of research, an effective HIV cure 
or vaccine does not exist. The main obstacle to an HIV cure is that the virus is 
able to stably integrate into the host genome and lay latent, enabling it to avoid 
recognition by the immune system [138]. Combination antiretroviral therapy 
(cART) is able to suppress viral replication while increasing survival and the 
quality of life of HIV infected individuals. However, once cART is withdrawn, a 
rapid and aggressive rebound of plasma viremia occurs [138]. Lifelong cART 
regimens are associated with toxicity [325] chronic inflammation and aging 
related comorbidities [326, 327]. New approaches to HIV eradication are needed 
with the goal of achieving a functional or sterilizing cure that does not necessitate 
dependence of cART. 
 Several lines of evidence indicate that cytotoxic CD8 T cells significantly 
contribute to control of viral replication [163, 165, 169, 263-265]. However, 
chronic HIV infection is associated with an increased expression of negative 
checkpoint receptors (NCRs) on HIV-specific CD8 T cells in peripheral blood that 
leads to progressive loss of function, termed “T cell exhaustion” [2] which further 
contribute to immune dysfunction and viral persistence [176-178, 180, 207, 208]. 
Identifying additional NCRs that persist and can be targeted during chronic HIV 
infection is imperative to the future of HIV cure strategies. 
 The extremely stable reservoir of latently infected memory CD4 T cells 
that harbor replication competent HIV provirus [328] remains a major barrier to 
HIV eradication. Current HIV cure strategies focus on the “shock and kill” 
approach. Small pharmacological compounds are clinically being evaluated to 
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reactivate (shock) latent HIV provirus without inducing host cell activation in order 
to expose them to the immune system for elimination (kill) [1]. However, there is 
little impact on the size of the latent reservoir in small clinical trials of latency 
reversing agents [202, 203, 206]. This suggests that additional immune 
mechanisms may be required to enhance the clearance of virally infected cells. 
 The main purpose of this dissertation was to evaluate the expression and 
function of the T -cell immunoreceptor with immunoglobulin and ITIM domains 
(TIGIT; also known as Vsig9, Vstm3 or WUCAM) in the context of HIV infection. 
The goal of this study was to identify clinically targetable pathways to reinvigorate 
robust anti-HIV responses during enhanced “shock and kill” eradication 
strategies. The long-term goal of this study was to understand immune 
dysfunction that contributes to HIV disease progression and pathogenesis. 
 The first objective focused on the T cell phenotype expression of TIGIT in 
the context of HIV infection. Peripheral blood mononuclear cells (PBMCs) were 
collected from individuals with varying stages of HIV disease progression and 
matched to HIV-uninfected individuals. We demonstrated that an expansion of 
TIGIT+ CD8 T cells during chronic HIV infection despite viral suppression 
strongly correlated with disease progression. We also show that gamma chain 
cytokines have the potent ability to increase the expression of TIGIT in the 
context of HIV infection. Furthermore, TIGIT was co-expressed with PD-1 on 
HIV-specific CD8 T cells across several HLA-restricted HIV epitopes. These data 
suggest that TIGIT and PD-1 may play a dominant role in negatively regulating 
broad anti-HIV CD8 T cell responses. We next assessed the functional capacity 
of TIGIT expressing HIV-specific CD8 T cells and found them to be impaired in 
the ability to generate anti-HIV effector immune responses. Moreover, CD4 T 
cells expressing TIGIT strongly correlated with the CD4 HIV DNA content, 
suggesting TIGIT may be involved in maintaining the viral reservoir by 
suppressing CD4 T cell activation. The work reported here indicates that the 
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TIGIT pathway is involved in HIV disease progression and is responsible for 
immune dysfunction and viral persistence.  
 The second objective was to evaluate the TIGIT pathway in the 
physiologically relevant Rhesus macaque (RM) nonhuman primate model of 
HIV/AIDS. Lymphocytes from peripheral blood and lymphoid tissues derived from 
SIV infected RMs were used to evaluate the expression and function of rhesus-
TIGIT (rhTIGIT). We cloned rhTIGIT and show an 88.11% amino acid homology 
with human TIGIT and reasoned that expression and function would mimic 
human TIGIT during HIV infection. We observed elevated levels of rhTIGIT+ CD8 
T cells in the periphery with a significant elevation in lymphoid tissues, which 
correlated with plasma viremia in SIV-infected RMs compared to SIV-uninfected 
controls. Moreover, rhTIGIT was regulated by gamma chain cytokines, similar to 
human TIGIT. We also observed that TIGIT co-expressed with rhesus PD-1 on 
SIV-specific CD8 T cells and rhTIGIT+ CD8 T cells failed to respond to SIV 
peptides. These data recapitulated the observations of human TIGIT during HIV 
infection and characterized a preclinical model to study the in vivo safety and 
efficacy of interfering with the TIGIT pathway in enhanced “shock and kill” HIV 
eradication strategies. 
 The third objective aimed to evaluate the effects of interfering with the 
TIGIT and PD-1 pathways to restore existing anti-HIV/SIV T cell effector 
functions. Clinically validated blocking monoclonal antibodies (mAbs) against 
TIGIT and PD-L1 were gifted to us in order to investigate blockade strategies in 
vitro. Blocking mAbs combined with our HIV peptide stimulation assay resulted in 
significant reinvigoration of pre-existing anti-HIV CD8 T cell effector functions 
when blocking a single or combination of TIGIT and PD-1 pathways. Anti-HIV 
CD8 T cell interferon gamma responses were significantly increased when TIGIT 
or PD-1 pathways were blocked, while a combination of anti-TIGIT and PD-L1 
significantly increased CD8 T cell proliferation. In parallel, these data were 
repeated in restoring SIV-specific CD8 effector functions by TIGIT and PD-L1 
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blockade in RMs. Our data indicates we can reverse T cell exhaustion and 
restore existing anti-HIV CD8 T cell effector functions to potentially allow them to 
more potently target HIV infected cells. 
 Our final objective was to evaluate the magnitude of peripheral CD8 T cell 
reinvigoration by TIGIT blockade to the expression of TIGIT with TIGIT ligands in 
peripheral blood and gut tissues. We observed a dynamic range in the 
restoration of CD8 T cell effector functions with TIGIT and PD-L1 blockade with 
no correlation between CD8 TIGIT or TIGIT ligand expression in the periphery. 
Similarly, in cancer immunotherapy, PD-L1 tumor expression as a pretreatment 
predictor of PD-1 blockade remains suboptimal [329, 330]. Studies characterizing 
immune function in the periphery have provided insight into HIV pathogenesis, 
however circulating lymphocytes only represent about 25% of the body’s total 
lymphocyte with a majority of them residing in gut tissues [278]. We generated 
single cell suspensions from rectosigmoid biopsies and evaluated the expression 
of TIGIT and TIGIT ligands in the context of PD-1. We observed tissue specific 
differences during HIV infection in the expression of TIGIT and PD-1 in addition 
to their respective ligands PVR and PD-L1. Interestingly, TIGIT had previously 
been shown to interact with Fusobacteria Fap2 to inhibit immune clearance of 
colon adenocarcinoma [290]. We further evaluated the microbiota composition 
and observed a significant increase in the abundance of Fusobacteria compared 
to HIV-uninfected controls. Bivariate analysis revealed that the magnitude of 
peripheral CD8 T cell reinvigoration by TIGIT blockade was correlated with 
RMMC PD-L1 pDC expression and the Fusobacteria abundance. Our data 
indicates that RMMC tissue immune parameters and microbiota composition may 
predict which individuals will respond to TIGIT blockade therapy as part of the 
enhanced “shock and kill” eradication strategies. 
 In conclusion, the information gained from these studies provides 
additional insight into the mechanisms driving HIV-associated immune 
dysfunction. Efforts to understand CD8 T cell exhaustion in the clearance of HIV 
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infection remain paramount in the search for an HIV cure. In addition, this data 
provides the rationale for further investigation into the role that TIGIT plays in HIV 
immune dysfunction. It is our hope that a better understanding of this pathway 
will lead to the development of novel curative therapies.  
 
FUTURE PERSPECTIVES 
 
 With data generated in this dissertation, we will be exploring the in vitro 
and in vivo killing of HIV infected cells with a NIH funded R21/33 
(1R21AI122393-01 PI: Lishomwa Ndhlovu). In the R21 phase we propose to 
determine the ability of TIGIT and PD-L1 blockade to reinvigorate the antiviral 
efficacy in vitro and deplete or inactivate HIV/SIV latently activated cells by 
enhancing anti-HIV/SIV CD8 T cell effector functions. In the R33 phase we will 
test the ability of TIGIT and PD-L1 blockade to clear the latent reservoir during 
fully suppressive cART in the SIV-infected Rhesus macaque model of HIV/AIDS. 
These studies are the first steps towards a novel approach that may lead to a 
sustained or functional HIV cure.  
 In addition to these studies we aim to elucidate the role of T cell 
immunometabolism and T cell reinvigoration. T cells undergo dramatic metabolic 
changes to meet the energy demands of and effective antiviral responses [331]. 
Interestingly, engagement of PD-1 results in an altered T cell metabolic 
reprograming and the inhibition of glycolysis, glutaminolysis, and amino acid 
metabolism [332]. Understanding the bioenergetics needs of CD8 T cells during 
immune checkpoint blockade (ICB) might improve therapies targeting TIGIT and 
further explain their capacity to be reinvigorated.  
 Furthermore, epigenetic mechanisms such as DNA methylation regulate 
transcriptional expression profiles in immune cells that ultimately direct cellular 
differentiation and function. Recent studies have revealed that gene expression 
of negative checkpoint receptors PD-1 and CTLA-4 are controlled by epigenetic 
regulation [333, 334]. Epigenetic studies have revealed that exhausted T cells 
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harbor a unique epigenetic and chromatin landscape profile relative to 
functioning T cells [335]. Unfortunately, there is lack of knowledge about how 
second tier immune checkpoint receptors such as TIGIT are epigenetically 
regulated and sustained during HIV infection. While TIGIT is upregulated on T 
cells during HIV infection, little is known about the genome-wide epigenetic 
states of TIGIT+ and TIGIT- CD8 and CD4 T cells. Furthermore, the impact of 
epigenetic manipulation on the CD8 T cell reinvigoration by TIGIT blockade is 
poorly defined. In future directions, we seek to define genome-wide epigenetic 
and transcriptional profiles in TIGIT+ and TIGIT- CD8 T cells subsets in cART 
suppressed HIV participants to provide a roadmap for candidate sites of the 
genome regulating dysfunctional TIGIT+ T cells. We will use genome-wide DNA 
methylation profiling of TIGIT+ and TIGIT- CD8 T cells from HIV-infected 
individuals to define the DNA methylation landscape. These reference 
methylomes will reveal a distinct DNA methylation state of CD8 T cells that may 
be a target for epigenetic manipulation.  
 This dissertation has demonstrated a prominent role for ICB during 
chronic HIV infection. However, there is a need to better understand the 
mechanisms by which ICB offers benefits that are less toxic but retain optimal 
anti-tumor and anti-viral efficacy for all patients. In the future, we plan to use 
integrated cellular, transcriptional, and epigenetic profiling of HIV-specific CD8 T 
cells to provide a mechanistic insight into ICB in the setting of HIV infection. 
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